First Header Logo Second Header Logo

Eric D. Hsi MD

TitleProfessor
InstitutionWake Forest School of Medicine
DepartmentPathology
Address
vCardDownload vCard
    Other Positions
    TitleChair
    InstitutionWake Forest School of Medicine
    DepartmentPathology


    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Foucar K, Bagg A, Bueso-Ramos CE, George T, Hasserjian RP, Hsi ED, Orazi A, Tam W, Wang SA, Weinberg OK, Arber DA. Guide to the Diagnosis of Myeloid Neoplasms: A Bone Marrow Pathology Group Approach. Am J Clin Pathol. 2023 Jun 30. PMID: 37391178.
      Citations:    
    2. Epperla N, Switchenko J, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Mathews S, Burkart M, Karmali R, Sawalha Y, Hill BT, Ghosh N, Park SI, Bond DA, Hamadani M, Fenske TS, Martin P, Malecek MK, Kahl BS, Flowers CR, Link BK, Kaplan LD, Inwards DJ, Feldman AL, Hsi ED, Maddocks K, Blum KA, Bartlett NL, Cerhan JR, Leonard JP, Habermann TM, Maurer MJ, Cohen JB. Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma. Blood Adv. 2023 Jun 13; 7(11):2287-2296. PMID: 36516079.
      Citations:    
    3. Nichols MM, Ondrejka SL, Patil S, Durkin L, Hill BT, Hsi ED. Ki67 proliferation index in follicular lymphoma is associated with favorable outcome in patients treated with R-CHOP. Leuk Lymphoma. 2023 May 24; 1-9. PMID: 37226602.
      Citations:    
    4. Kirtek T, Chen W, Laczko D, Bagg A, Koduru P, Foucar K, Venable E, Nichols M, Rogers HJ, Tam W, Orazi A, Hsi ED, Hasserjian RP, Wang SA, Arber DA, Weinberg OK. Acute leukemias with complex karyotype show a similarly poor outcome independent of mixed, myeloid or lymphoblastic immunophenotype: A study from the Bone Marrow Pathology Group. Leuk Res. 2023 Jul; 130:107309. PMID: 37210875.
      Citations:    
    5. Li Y, Xu-Monette ZY, Abramson J, Sohani AR, Bhagat G, Tzankov A, Visco C, Zhang S, Dybkaer K, Pan Z, Xu M, Tam W, Zu Y, Hsi ED, Hagemeister FB, Go H, van Krieken JH, Winter JN, Ponzoni M, Ferreri AJM, Møller MB, Piris MA, Wang Y, Zhang M, Young KH. EBV-positive DLBCL frequently harbors somatic mutations associated with clonal hematopoiesis of indeterminate potential. Blood Adv. 2023 Apr 11; 7(7):1308-1311. PMID: 36399513.
      Citations:    
    6. Ramia de Cap M, Wu LP, Hirt C, Pihan GA, Patel SS, Tam W, Bueso-Ramos CE, Kanagal-Shamanna R, Raess PW, Siddon A, Narayanan D, Morgan EA, Pinkus GS, Mason EF, Hsi ED, Rogers HJ, Toth L, Foucar K, Hurwitz SN, Bagg A, Rets A, George TI, Orazi A, Arber DA, Hasserjian RP, Weinberg OK. Myeloid sarcoma with NPM1 mutation may be clinically and genetically distinct from AML with NPM1 mutation: a study from the Bone Marrow Pathology Group. Leuk Lymphoma. 2023 May; 64(5):972-980. PMID: 36960680.
      Citations:    
    7. Kaseb H, Visconte V, Socha DS, Crane GM, Durkin L, Cook JR, Maciejewski JP, Hsi ED, Rogers HJ. The clinicopathologic significance of NPM1 mutation and ability to detect mutated NPM1 by immunohistochemistry in non-AML myeloid neoplasms. Genes Chromosomes Cancer. 2023 Mar 23. PMID: 36959701.
      Citations:    
    8. Suknuntha K, Geyer JT, Patel KP, Weinberg OK, Rogers HJ, Lake JI, Lauridsen L, Patel JL, Kluk MJ, Arber DA, Hsi ED, Bagg A, Bueso-Ramos C, Orazi A. Clinicopathologic characteristics of myeloproliferative neoplasms with JAK2 exon 12 mutation. Leuk Res. 2023 Apr; 127:107033. PMID: 36774789.
      Citations:    
    9. Al-Ghamdi YA, Lake J, Bagg A, Thakral B, Wang SA, Bueso-Ramos C, Masarova L, Verstovsek S, Rogers HJ, Hsi ED, Gralewski JH, Chabot-Richards D, George TI, Rets A, Hasserjian RP, Weinberg OK, Parilla M, Arber DA, Padilla O, Orazi A, Tam W. Triple-Negative Primary Myelofibrosis: A Bone Marrow Pathology Group Study. Mod Pathol. 2023 Mar; 36(3):100016. PMID: 36788093.
      Citations:    
    10. Zhang X, Hsi ED, Crane GM, Cheng YW. Biallelic TET2 mutations and canonical ASXL1 mutations are frequent and cooccur in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): An institutional experience and review of literature. EJHaem. 2023 Feb; 4(1):236-240. PMID: 36819168.
      Citations:    
    11. Cantu MD, Kanagal-Shamanna R, Wang SA, Kadia T, Bueso-Ramos CE, Patel SS, Geyer JT, Tam W, Madanat Y, Li P, George TI, Nichols MM, Rogers HJ, Liu YC, Aggarwal N, Kurzer JH, Maracaja DLV, Hsi ED, Zaiem F, Babu D, Foucar K, Laczko D, Bagg A, Orazi A, Arber DA, Hasserjian RP, Weinberg OK. Clinicopathologic and Molecular Analysis of Normal Karyotype Therapy-Related and De Novo Acute Myeloid Leukemia: A Multi-Institutional Study by the Bone Marrow Pathology Group. JCO Precis Oncol. 2023 Jan; 7:e2200400. PMID: 36689697.
      Citations:    
    12. Sander B, Campo E, Hsi ED. Correction to: Chronic lymphocytic leukaemia/small lymphocytic lymphoma and mantle cell lymphoma: from early lesions to transformation. Virchows Arch. 2023 Jan; 482(1):147-148. PMID: 36633689.
      Citations:    
    13. Gru AA, Lim MS, Dogan A, Horwitz SM, Delabie J, Fu K, Peker D, Reddy VVB, Xu ML, Vij K, Slack GW, Miranda RN, Jagadeesh D, Lisano JM, Hsi ED, Torlakovic E. Best Practices in CD30 Immunohistochemistry Testing, Interpretation, and Reporting: An Expert Panel Consensus. Arch Pathol Lab Med. 2023 Jan 01; 147(1):79-86. PMID: 35472771.
      Citations:    
    14. Sander B, Campo E, Hsi ED. Chronic lymphocytic leukaemia/small lymphocytic lymphoma and mantle cell lymphoma: from early lesions to transformation. Virchows Arch. 2023 Jan; 482(1):131-145. PMID: 36454275.
      Citations:    
    15. de Leval L, Alizadeh AA, Bergsagel PL, Campo E, Davies A, Dogan A, Fitzgibbon J, Horwitz SM, Melnick AM, Morice WG, Morin RD, Nadel B, Pileri SA, Rosenquist R, Rossi D, Salaverria I, Steidl C, Treon SP, Zelenetz AD, Advani RH, Allen CE, Ansell SM, Chan WC, Cook JR, Cook LB, d'Amore F, Dirnhofer S, Dreyling M, Dunleavy K, Feldman AL, Fend F, Gaulard P, Ghia P, Gribben JG, Hermine O, Hodson DJ, Hsi ED, Inghirami G, Jaffe ES, Karube K, Kataoka K, Klapper W, Kim WS, King RL, Ko YH, LaCasce AS, Lenz G, Martin-Subero JI, Piris MA, Pittaluga S, Pasqualucci L, Quintanilla-Martinez L, Rodig SJ, Rosenwald A, Salles GA, San-Miguel J, Savage KJ, Sehn LH, Semenzato G, Staudt LM, Swerdlow SH, Tam CS, Trotman J, Vose JM, Weigert O, Wilson WH, Winter JN, Wu CJ, Zinzani PL, Zucca E, Bagg A, Scott DW. Genomic profiling for clinical decision making in lymphoid neoplasms. Blood. 2022 Nov 24; 140(21):2193-2227. PMID: 36001803.
      Citations:    
    16. Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, Brousset P, Cerroni L, de Leval L, Dirnhofer S, Dogan A, Feldman AL, Fend F, Friedberg JW, Gaulard P, Ghia P, Horwitz SM, King RL, Salles G, San-Miguel J, Seymour JF, Treon SP, Vose JM, Zucca E, Advani R, Ansell S, Au WY, Barrionuevo C, Bergsagel L, Chan WC, Cohen JI, d'Amore F, Davies A, Falini B, Ghobrial IM, Goodlad JR, Gribben JG, Hsi ED, Kahl BS, Kim WS, Kumar S, LaCasce AS, Laurent C, Lenz G, Leonard JP, Link MP, Lopez-Guillermo A, Mateos MV, Macintyre E, Melnick AM, Morschhauser F, Nakamura S, Narbaitz M, Pavlovsky A, Pileri SA, Piris M, Pro B, Rajkumar V, Rosen ST, Sander B, Sehn L, Shipp MA, Smith SM, Staudt LM, Thieblemont C, Tousseyn T, Wilson WH, Yoshino T, Zinzani PL, Dreyling M, Scott DW, Winter JN, Zelenetz AD. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood. 2022 Sep 15; 140(11):1229-1253. PMID: 35653592.
      Citations:    
    17. King RL, Hsi ED, Chan WC, Piris MA, Cook JR, Scott DW, Swerdlow SH. Diagnostic approaches and future directions in Burkitt lymphoma and high-grade B-cell lymphoma. Virchows Arch. 2023 Jan; 482(1):193-205. PMID: 36057749.
      Citations:    
    18. Merrill R, Puckett M, Morrow WP, Hsi ED, Powell J, Li Z, Vaidya R, Strowd R. Clinical Reasoning: A 65-Year-Old Woman With Cancer History and Wrist Drop. Neurology. 2022 Sep 27; 99(13):570-576. PMID: 35851256.
      Citations:    
    19. Gisriel SD, Yuan J, Braunberger RC, Maracaja DLV, Chen X, Wu X, McCracken J, Chen M, Xie Y, Brown LE, Li P, Zhou Y, Sethi T, McHenry A, Hauser RG, Paulson N, Tang H, Hsi ED, Wang E, Zhang QY, Young KH, Xu ML, Pan Z. Human herpesvirus 8-negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristics. Mod Pathol. 2022 Oct; 35(10):1411-1422. PMID: 35562413.
      Citations:    
    20. Kanagal-Shamanna R, Orazi A, Hasserjian RP, Arber DA, Reichard K, Hsi ED, Bagg A, Rogers HJ, Geyer J, Darbaniyan F, Do KA, Devins KM, Pozdnyakova O, George TI, Cin PD, Greipp PT, Routbort MJ, Patel K, Garcia-Manero G, Verstovsek S, Medeiros LJ, Wang SA, Bueso-Ramos C. Correction to: Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group. Mod Pathol. 2022 May; 35(5):705. PMID: 34903824.
      Citations:    
    21. Patel N, Slack GW, Bodo J, Ben-Neriah S, Villa D, Durkin L, Socha D, Steidl C, Hsi ED. Immune Escape Mechanisms in Intravascular Large B-Cell Lymphoma: A Molecular Cytogenetic and Immunohistochemical Study. Am J Clin Pathol. 2022 Apr 01; 157(4):578-585. PMID: 34724028.
      Citations:    
    22. Xu-Monette ZY, Wei L, Fang X, Au Q, Nunns H, Nagy M, Tzankov A, Zhu F, Visco C, Bhagat G, Dybkaer K, Chiu A, Tam W, Zu Y, Hsi ED, Hagemeister FB, Sun X, Han X, Go H, Ponzoni M, Ferreri AJM, Møller MB, Parsons BM, van Krieken JH, Piris MA, Winter JN, Li Y, Xu B, Albitar M, You H, Young KH. Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma. Clin Cancer Res. 2022 Mar 01; 28(5):972-983. PMID: 34980601.
      Citations:    
    23. Baker JA, Sireci AN, Marella N, Cannon HK, Marquart TJ, Holzer TR, Reising LO, Cook JD, Wijayawardana SR, Bodo J, Hsi ED, Schade AE, Oakley GJ. Analytical Accuracy of RET Fusion Detection by Break-Apart Fluorescence In Situ Hybridization. Arch Pathol Lab Med. 2022 Mar 01; 146(3):351-359. PMID: 34232984.
      Citations:    
    24. Sun LD, Polly S, Ko JS, Ricci K, Hsi ED, Cooper KD, Fernandez AP. Analysis of clinical and serologic predictors of response to extracorporeal photopheresis therapy in cutaneous T-cell lymphoma patients. Photodermatol Photoimmunol Photomed. 2022 Nov; 38(6):600-603. PMID: 35132696.
      Citations:    
    25. Albitar M, Zhang H, Goy A, Xu-Monette ZY, Bhagat G, Visco C, Tzankov A, Fang X, Zhu F, Dybkaer K, Chiu A, Tam W, Zu Y, Hsi ED, Hagemeister FB, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Parsons BM, van Krieken JH, Piris MA, Winter JN, Li Y, Xu B, Young KH. Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms. Blood Cancer J. 2022 Feb 01; 12(2):25. PMID: 35105854.
      Citations:    
    26. Habermehl GK, Durkin L, Hsi ED. A Tissue Counterpart to Monoclonal B-Cell Lymphocytosis. Arch Pathol Lab Med. 2021 Dec 01; 145(12):1544-1551. PMID: 33720326.
      Citations:    
    27. Kanagal-Shamanna R, Orazi A, Hasserjian RP, Arber DA, Reichard K, Hsi ED, Bagg A, Rogers HJ, Geyer J, Darbaniyan F, Do KA, Devins KM, Pozdnyakova O, George TI, Cin PD, Greipp PT, Routbort MJ, Patel K, Garcia-Manero G, Verstovsek S, Medeiros LJ, Wang SA, Bueso-Ramos C. Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group. Mod Pathol. 2022 Apr; 35(4):470-479. PMID: 34775472.
      Citations:    
    28. Vega F, Amador C, Chadburn A, Hsi ED, Slack G, Medeiros LJ, Feldman AL. Genetic profiling and biomarkers in peripheral T-cell lymphomas: current role in the diagnostic work-up. Mod Pathol. 2022 Mar; 35(3):306-318. PMID: 34584212.
      Citations:    
    29. Gruver AM, Westfall MD, Ackermann BL, Hill S, Morrison RD, Bodo J, Lai KK, Gemperline DC, Hsi ED, Liebler DC, Schmitz J, Benschop RJ. Proteomic characterisations of ulcerative colitis endoscopic biopsies associate with clinically relevant histological measurements of disease severity. J Clin Pathol. 2022 Sep; 75(9):636-642. PMID: 34353876.
      Citations:    
    30. You H, Xu-Monette ZY, Wei L, Nunns H, Nagy ML, Bhagat G, Fang X, Zhu F, Visco C, Tzankov A, Dybkaer K, Chiu A, Tam W, Zu Y, Hsi ED, Hagemeister FB, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Parsons BM, Van Krieken JH, Piris MA, Winter JN, Li Y, Au Q, Xu B, Albitar M, Young KH. Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma. Oncoimmunology. 2021; 10(1):1928365. PMID: 34350060.
      Citations:    
    31. Duns G, Viganò E, Ennishi D, Sarkozy C, Hung SS, Chavez E, Takata K, Rushton C, Jiang A, Ben-Neriah S, Woolcock BW, Slack GW, Hsi ED, Craig JW, Hilton LK, Shah SP, Farinha P, Mottok A, Gascoyne RD, Morin RD, Savage KJ, Scott DW, Steidl C. Characterization of DLBCL with a PMBL gene expression signature. Blood. 2021 Jul 15; 138(2):136-148. PMID: 33684939.
      Citations:    
    32. Gurnari C, Pagliuca S, Durkin L, Terkawi L, Awada H, Kongkiatkamon S, Zawit M, Hsi ED, Carraway HE, Rogers HJ, Visconte V, Maciejewski JP. Vacuolization of hematopoietic precursors: an enigma with multiple etiologies. Blood. 2021 Jul 01; 137(26):3685-3689. PMID: 33690844.
      Citations:    
    33. Tang G, Tam W, Short NJ, Bose P, Wu D, Hurwitz SN, Bagg A, Rogers HJ, Hsi ED, Quesada AE, Wang W, Miranda RN, Bueso-Ramos CE, Medeiros LJ, Nardi V, Hasserjian RP, Arber DA, Orazi A, Foucar K, Wang SA. Myeloid/lymphoid neoplasms with FLT3 rearrangement. Mod Pathol. 2021 Sep; 34(9):1673-1685. PMID: 33990705.
      Citations:    
    34. Hamadeh F, Smith MR, Hsi ED. Crystal-storing histiocytes in ascites leading to a diagnosis of plasma cell myeloma. Diagn Cytopathol. 2021 Sep; 49(9):E336-E339. PMID: 33945666.
      Citations:    
    35. Goyal T, Ondrejka SL, Bodo J, Durkin L, Hsi ED. Lack of activation-induced cytidine deaminase expression in in situ follicular neoplasia. Haematologica. 2021 Apr 01; 106(4):1212-1215. PMID: 32817287.
      Citations:    
    36. Sohani AR, Maurer MJ, Giri S, Pitcher B, Chadburn A, Said JW, Bartlett NL, Czuczman MS, Martin P, Rosenbaum CA, Jung SH, Leonard JP, Cheson BD, Hsi ED. Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti-CD20-based Biological Therapy. Am J Surg Pathol. 2021 Mar 01; 45(3):384-393. PMID: 33136585.
      Citations:    
    37. Patel BJ, Barot SV, Xie Y, Cook JR, Carraway HE, Hsi ED. Impact of next generation sequencing results on clinical management in patients with hematological disorders. Leuk Lymphoma. 2021 Jul; 62(7):1702-1710. PMID: 33533694.
      Citations:    
    38. Deng M, Xu-Monette ZY, Pham LV, Wang X, Tzankov A, Fang X, Zhu F, Visco C, Bhagat G, Dybkaer K, Chiu A, Tam W, Zu Y, Hsi ED, You H, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Parsons BM, Hagemeister F, van Krieken JH, Piris MA, Winter JN, Li Y, Xu B, Liu P, Young KH. Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents. Mol Cancer Res. 2021 Feb; 19(2):249-260. PMID: 33154093.
      Citations:    
    39. Deng M, Zhang M, Xu-Monette ZY, Pham LV, Tzankov A, Visco C, Fang X, Bhagat G, Zhu F, Dybkaer K, Chiu A, Tam W, Zu Y, Hsi ED, Choi WWL, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Parsons BM, van Krieken JH, Piris MA, Winter JN, Hagemeister F, Alinari L, Li Y, Andreeff M, Xu B, Young KH. XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53. J Hematol Oncol. 2020 Nov 04; 13(1):148. PMID: 33148342.
      Citations:    
    40. Kapoor I, Bodo J, Hill BT, Hsi ED, Almasan A. Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance. Cell Death Dis. 2020 Nov 02; 11(11):941. PMID: 33139702.
      Citations:    
    41. Socha DS, Zhao X, Bodo J, Durkin L, Hsi ED. Decreased BIM expression in BCL2-negative follicular lymphoma: a potential mechanism for resistance to apoptosis. Hum Pathol. 2021 Jan; 107:1-8. PMID: 33039369.
      Citations:    
    42. Vega F, Amador C, Chadburn A, Feldman AL, Hsi ED, Wang W, Medeiros LJ. American Registry of Pathology Expert Opinions: Recommendations for the diagnostic workup of mature T cell neoplasms. Ann Diagn Pathol. 2020 Dec; 49:151623. PMID: 32947231.
      Citations:    
    43. Bruehl FK, Azzato E, Durkin L, Farkas DH, Hsi ED, Ondrejka SL. Inflammatory Pseudotumor-Like Follicular/Fibroblastic Dendritic Cell Sarcomas of the Spleen Are EBV-Associated and Lack Other Commonly Identifiable Molecular Alterations. Int J Surg Pathol. 2021 Jun; 29(4):443-446. PMID: 32787485.
      Citations:    
    44. Gu X, Tohme R, Tomlinson B, Sakre N, Hasipek M, Durkin L, Schuerger C, Grabowski D, Zidan AM, Radivoyevitch T, Hong C, Carraway H, Hamilton B, Sobecks R, Patel B, Jha BK, Hsi ED, Maciejewski J, Saunthararajah Y. Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network. Leukemia. 2021 Apr; 35(4):1023-1036. PMID: 32770088.
      Citations:    
    45. Zhao X, Bodo J, Chen R, Durkin L, Souers AJ, Phillips DC, Hsi ED. Inhibition of cyclin-dependent kinase 9 synergistically enhances venetoclax activity in mantle cell lymphoma. EJHaem. 2020 Jul; 1(1):161-169. PMID: 35847704.
      Citations:    
    46. Xu-Monette ZY, Zhang H, Zhu F, Tzankov A, Bhagat G, Visco C, Dybkaer K, Chiu A, Tam W, Zu Y, Hsi ED, You H, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Parsons BM, van Krieken JH, Piris MA, Winter JN, Hagemeister FB, Shahbaba B, De Dios I, Zhang H, Li Y, Xu B, Albitar M, Young KH. A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL. Blood Adv. 2020 Jul 28; 4(14):3391-3404. PMID: 32722783.
      Citations:    
    47. Ok CY, Trowell KT, Parker KG, Moser K, Weinberg OK, Rogers HJ, Reichard KK, George TI, Hsi ED, Bueso-Ramos CE, Tam W, Orazi A, Bagg A, Arber DA, Hasserjian RP, Wang SA. Chronic myeloid neoplasms harboring concomitant mutations in myeloproliferative neoplasm driver genes (JAK2/MPL/CALR) and SF3B1. Mod Pathol. 2021 Jan; 34(1):20-31. PMID: 32694616.
      Citations:    
    48. Ennishi D, Hsi ED, Steidl C, Scott DW. Toward a New Molecular Taxonomy of Diffuse Large B-cell Lymphoma. Cancer Discov. 2020 Sep; 10(9):1267-1281. PMID: 32616477.
      Citations:    
    49. Schöder H, Polley MC, Knopp MV, Hall N, Kostakoglu L, Zhang J, Higley HR, Kelloff G, Liu H, Zelenetz AD, Cheson BD, Wagner-Johnston N, Kahl BS, Friedberg JW, Hsi ED, Leonard JP, Schwartz LH, Wilson WH, Bartlett NL. Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial. Blood. 2020 Jun 18; 135(25):2224-2234. PMID: 32232481.
      Citations:    
    50. Nomani L, Cotta CV, Hsi ED, Ferry JA, Cook JR. Extranodal Marginal Zone Lymphoma of the Central Nervous System Includes Parenchymal-Based Cases With Characteristic Features. Am J Clin Pathol. 2020 Jun 08; 154(1):124-132. PMID: 32318699.
      Citations:    
    51. Ondrejka SL, Hsi ED. Chronic active Epstein-Barr virus infection: A heterogeneous entity requiring a high index of suspicion for diagnosis. Int J Lab Hematol. 2020 Jun; 42 Suppl 1:99-106. PMID: 32543060.
      Citations:    
    52. Ha CS, LeBlanc M, Schöder H, Pinnix CC, Bartlett NL, Evens AM, Hsi ED, Rimsza L, Knopp MV, Zhang J, Leonard JP, Kahl BS, Li H, Smith S, Constine LS, Friedberg JW. Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: a secondary analysis of SWOG S0816. Leuk Lymphoma. 2020 Oct; 61(10):2442-2447. PMID: 32452714.
      Citations:    
    53. Lansigan F, Horwitz SM, Pinter-Brown LC, Carson KR, Shustov AR, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Foss FM. Outcomes of Patients with Transformed Mycosis Fungoides: Analysis from a Prospective Multicenter US Cohort Study. Clin Lymphoma Myeloma Leuk. 2020 Nov; 20(11):744-748. PMID: 32532611.
      Citations:    
    54. Rogers HJ, Wang X, Xie Y, Davis AR, Thakral B, Wang SA, Borthakur G, Cantu MD, Margolskee EM, Philip JKS, Sukhanova M, Bagg A, Bueso-Ramos CE, Orazi A, Arber DA, Hsi ED, Hasserjian RP. Comparison of therapy-related and de novo core binding factor acute myeloid leukemia: A bone marrow pathology group study. Am J Hematol. 2020 Jul; 95(7):799-808. PMID: 32249963.
      Citations:    
    55. Foucar K, Hsi ED, Wang SA, Rogers HJ, Hasserjian RP, Bagg A, George TI, Bassett RL, Peterson LC, Morice WG, Arber DA, Orazi A, Bueso-Ramos CE. Concordance among hematopathologists in classifying blasts plus promonocytes: A bone marrow pathology group study. Int J Lab Hematol. 2020 Aug; 42(4):418-422. PMID: 32297416.
      Citations:    
    56. Patel N, Durkin L, Bodo J, Hsi ED. Immunohistochemical Expression of Lymphoid Enhancer Binding Factor 1 in CD5-Positive Marginal Zone, Lymphoplasmacytic, and Follicular Lymphomas. Am J Clin Pathol. 2020 Apr 15; 153(5):646-655. PMID: 31953940.
      Citations:    
    57. Kaplan LD, Maurer MJ, Stock W, Bartlett NL, Fulton N, Pettinger A, Byrd JC, Blum KA, LaCasce AS, Hsi ED, Liu YT, Scott DW, Hurd D, Ruppert AS, Hernandez-Ilizaliturri F, Leonard JP, Cheson BD. Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: CALGB/Alliance 50403. Am J Hematol. 2020 06; 95(6):583-593. PMID: 32170769.
      Citations:    
    58. Hu Y, Liu H, Fang C, Li C, Xhyliu F, Dysert H, Bodo J, Habermehl G, Russell BE, Li W, Chappell M, Jiang X, Ondrejka SL, Hsi ED, Maciejewski JP, Yi Q, Anderson KC, Munshi NC, Ao G, Valent JN, Lin J, Zhao J. Targeting of CD38 by the Tumor Suppressor miR-26a Serves as a Novel Potential Therapeutic Agent in Multiple Myeloma. Cancer Res. 2020 May 15; 80(10):2031-2044. PMID: 32193289.
      Citations:    
    59. Dermawan JK, Hsi ED, Sethi S, Arrossi AV. Endobronchial pseudocarcinomatous hyperplasia mimicking squamous cell carcinoma associated with primary pulmonary ALK-negative anaplastic large cell lymphoma. Histopathology. 2020 Apr; 76(5):781-784. PMID: 31705818.
      Citations:    
    60. Xu ML, Gabali A, Hsi ED, Fedoriw Y, Vij K, Salama ME, Ramchandren R, O'Malley D, Wick MR, Battistella M, Gru AA. Practical Approaches on CD30 Detection and Reporting in Lymphoma Diagnosis. Am J Surg Pathol. 2020 Feb; 44(2):e1-e14. PMID: 31567279.
      Citations:    
    61. Phillips DC, Jin S, Gregory GP, Zhang Q, Xue J, Zhao X, Chen J, Tong Y, Zhang H, Smith M, Tahir SK, Clark RF, Penning TD, Devlin JR, Shortt J, Hsi ED, Albert DH, Konopleva M, Johnstone RW, Leverson JD, Souers AJ. A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies. Leukemia. 2020 Jun; 34(6):1646-1657. PMID: 31827241.
      Citations:    
    62. Kapoor I, Li Y, Sharma A, Zhu H, Bodo J, Xu W, Hsi ED, Hill BT, Almasan A. Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies. Cell Death Dis. 2019 Dec 04; 10(12):924. PMID: 31801949.
      Citations:    
    63. Panea RI, Love CL, Shingleton JR, Reddy A, Bailey JA, Moormann AM, Otieno JA, Ong'echa JM, Oduor CI, Schroeder KMS, Masalu N, Chao NJ, Agajanian M, Major MB, Fedoriw Y, Richards KL, Rymkiewicz G, Miles RR, Alobeid B, Bhagat G, Flowers CR, Ondrejka SL, Hsi ED, Choi WWL, Au-Yeung RKH, Hartmann W, Lenz G, Meyerson H, Lin YY, Zhuang Y, Luftig MA, Waldrop A, Dave T, Thakkar D, Sahay H, Li G, Palus BC, Seshadri V, Kim SY, Gascoyne RD, Levy S, Mukhopadyay M, Dunson DB, Dave SS. The whole-genome landscape of Burkitt lymphoma subtypes. Blood. 2019 Nov 07; 134(19):1598-1607. PMID: 31558468.
      Citations:    
    64. Valenzuela J, Yeaney GA, Hsi ED, Azzato EM, Peereboom DM, Singh AD. Large B-cell lymphoma of the uvea: Histopathologic variants and clinicopathologic correlation. Surv Ophthalmol. 2020; 65(3):361-370. PMID: 31676312.
      Citations:    
    65. Xu-Monette ZY, Li J, Xia Y, Crossley B, Bremel RD, Miao Y, Xiao M, Snyder T, Manyam GC, Tan X, Zhang H, Visco C, Tzankov A, Dybkaer K, Bhagat G, Tam W, You H, Hsi ED, van Krieken JH, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Piris MA, Winter JN, Medeiros JT, Xu B, Li Y, Kirsch I, Young KH. Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies. J Immunother Cancer. 2019 Oct 22; 7(1):272. PMID: 31640780.
      Citations:    
    66. Stephens DM, Li H, Schöder H, Straus DJ, Moskowitz CH, LeBlanc M, Rimsza LM, Bartlett NL, Evens AM, LaCasce AS, Barr PM, Knopp MV, Hsi ED, Leonard JP, Kahl BS, Smith SM, Friedberg JW. Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. Blood. 2019 Oct 10; 134(15):1238-1246. PMID: 31331918.
      Citations:    
    67. Soderquist CR, Patel N, Murty VV, Betman S, Aggarwal N, Young KH, Xerri L, Leeman-Neill R, Lewis SK, Green PH, Hsiao S, Mansukhani MM, Hsi ED, de Leval L, Alobeid B, Bhagat G. Genetic and phenotypic characterization of indolent T-cell lymphoproliferative disorders of the gastrointestinal tract. Haematologica. 2020 Jul; 105(7):1895-1906. PMID: 31558678.
      Citations:    
    68. Lansigan F, Horwitz SM, Pinter-Brown LC, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Shustov AR, Advani RH, Feldman T, Lechowicz MJ, Smith SM, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Park SI, Foss FM. Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry. Acta Haematol. 2020; 143(1):40-50. PMID: 31315113.
      Citations:    
    69. Basha BM, Hsi ED. Immunohistochemical Analysis of Endothelial Cells in Vascular Transformation of Lymph Node Sinuses: Vascular or Lymphatic Differentiation? Appl Immunohistochem Mol Morphol. 2019 Jul; 27(6):482-489. PMID: 29629951.
      Citations:    
    70. Blum KA, Polley MY, Jung SH, Dockter TJ, Anderson S, Hsi ED, Wagner-Johnston N, Christian B, Atkins J, Cheson BD, Leonard JP, Bartlett NL. Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance). Cancer. 2019 Oct 01; 125(19):3378-3389. PMID: 31174236.
      Citations:    
    71. Weinberg OK, Hasserjian RP, Baraban E, Ok CY, Geyer JT, Philip JKSS, Kurzer JH, Rogers HJ, Nardi V, Stone RM, Garcia JS, Hsi ED, Bagg A, Wang SA, Orazi A, Arber DA. Clinical, immunophenotypic, and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation: a study from the bone marrow pathology group. Mod Pathol. 2019 Sep; 32(9):1373-1385. PMID: 31000771.
      Citations:    
    72. Bartlett NL, Wilson WH, Jung SH, Hsi ED, Maurer MJ, Pederson LD, Polley MC, Pitcher BN, Cheson BD, Kahl BS, Friedberg JW, Staudt LM, Wagner-Johnston ND, Blum KA, Abramson JS, Reddy NM, Winter JN, Chang JE, Gopal AK, Chadburn A, Mathew S, Fisher RI, Richards KL, Schöder H, Zelenetz AD, Leonard JP. Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. J Clin Oncol. 2019 Jul 20; 37(21):1790-1799. PMID: 30939090.
      Citations:    
    73. Xu-Monette ZY, Xiao M, Au Q, Padmanabhan R, Xu B, Hoe N, Rodríguez-Perales S, Torres-Ruiz R, Manyam GC, Visco C, Miao Y, Tan X, Zhang H, Tzankov A, Wang J, Dybkær K, Tam W, You H, Bhagat G, Hsi ED, Ponzoni M, Ferreri AJM, Møller MB, Piris MA, van Krieken JH, Winter JN, Westin JR, Pham LV, Medeiros LJ, Rassidakis GZ, Li Y, Freeman GJ, Young KH. Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL. Cancer Immunol Res. 2019 Apr; 7(4):644-657. PMID: 30745366.
      Citations:    
    74. Hsi ED, Li H, Nixon AB, Schöder H, Bartlett NL, LeBlanc M, Smith S, Kahl BS, Leonard JP, Evens AM, Scott DW, Rimsza LM, Friedberg JW. Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study. Blood. 2019 Apr 18; 133(16):1762-1765. PMID: 30723079.
      Citations:    
    75. O'Connor OA, Özcan M, Jacobsen ED, Roncero JM, Trotman J, Demeter J, Masszi T, Pereira J, Ramchandren R, Beaven A, Caballero D, Horwitz SM, Lennard A, Turgut M, Hamerschlak N, d'Amore FA, Foss F, Kim WS, Leonard JP, Zinzani PL, Chiattone CS, Hsi ED, Trümper L, Liu H, Sheldon-Waniga E, Ullmann CD, Venkatakrishnan K, Leonard EJ, Shustov AR. Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma. J Clin Oncol. 2019 Mar 10; 37(8):613-623. PMID: 30707661.
      Citations:    
    76. Guo L, Bodo J, Durkin L, Hsi ED. Evaluation of PD1/PDL1 Expression and Their Clinicopathologic Association in EBV-associated Lymphoproliferative Disorders in Nonimmunosuppressed Patients. Appl Immunohistochem Mol Morphol. 2019 Feb; 27(2):101-106. PMID: 29084057.
      Citations:    
    77. Park SI, Horwitz SM, Foss FM, Pinter-Brown LC, Carson KR, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Advani RH, Feldman T, Lechowicz MJ, Smith SM, Lansigan F, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Shustov AR. The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study. Cancer. 2019 May 01; 125(9):1507-1517. PMID: 30694529.
      Citations:    
    78. Landsburg DJ, Hughes ME, Koike A, Bond D, Maddocks KJ, Guo L, Winter AM, Hill BT, Ondrejka SL, Hsi ED, Nasta SD, Svoboda J, Schuster SJ, Bogusz AM. Outcomes of patients with relapsed/refractory double-expressor B-cell lymphoma treated with ibrutinib monotherapy. Blood Adv. 2019 Jan 22; 3(2):132-135. PMID: 30651281.
      Citations:    
    79. Li L, Sun R, Miao Y, Tran T, Adams L, Roscoe N, Xu B, Manyam GC, Tan X, Zhang H, Xiao M, Tzankov A, Visco C, Dybkaer K, Bhagat G, Tam W, Hsi ED, van Krieken JH, You H, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Piris MA, Zhang M, Winter JN, Medeiros LJ, Rassidakis GZ, Vaupel CA, Li Y, Dakappagari N, Xu-Monette ZY, Young KH. PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program. Mod Pathol. 2019 Jun; 32(6):741-754. PMID: 30666052.
      Citations:    
    80. Seegmiller AC, Hsi ED, Craig FE. The current role of clinical flow cytometry in the evaluation of mature B-cell neoplasms. Cytometry B Clin Cytom. 2019 Jan; 96(1):20-29. PMID: 30549186.
      Citations:    
    81. Martín-Garcia D, Navarro A, Valdés-Mas R, Clot G, Gutiérrez-Abril J, Prieto M, Ribera-Cortada I, Woroniecka R, Rymkiewicz G, Bens S, de Leval L, Rosenwald A, Ferry JA, Hsi ED, Fu K, Delabie J, Weisenburger D, de Jong D, Climent F, O'Connor SJ, Swerdlow SH, Torrents D, Beltran S, Espinet B, González-Farré B, Veloza L, Costa D, Matutes E, Siebert R, Ott G, Quintanilla-Martinez L, Jaffe ES, López-Otín C, Salaverria I, Puente XS, Campo E, Beà S. CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1- mantle cell lymphoma. Blood. 2019 Feb 28; 133(9):940-951. PMID: 30538135.
      Citations:    
    82. Hsi ED. Intensive immunochemotherapy for high-risk aggressive B-cell lymphomas: MYC-rearrangements and beyond. Lancet Haematol. 2018 Dec; 5(12):e600-e601. PMID: 30501862.
      Citations:    
    83. Qu X, Li H, Braziel RM, Passerini V, Rimsza LM, Hsi ED, Leonard JP, Smith SM, Kridel R, Press O, Weigert O, LeBlanc M, Friedberg JW, Fang M. Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016. Blood. 2019 Jan 03; 133(1):81-93. PMID: 30446494.
      Citations:    
    84. Tang G, Sydney Sir Philip JK, Weinberg O, Tam W, Sadigh S, Lake JI, Margolskee EM, Rogers HJ, Miranda RN, Bueso-Ramos C C, Hsi ED, Orazi A, Hasserjian RP, Arber DA, Bagg A, Wang SA. Hematopoietic neoplasms with 9p24/JAK2 rearrangement: a multicenter study. Mod Pathol. 2019 Apr; 32(4):490-498. PMID: 30401948.
      Citations:    
    85. Czuczman MS, Leonard JP, Jung S, Johnson JL, Hsi ED, Byrd JC, Cheson BD. Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness. Ann Oncol. 2018 Nov 01; 29(11):2271. PMID: 29390097.
      Citations:    
    86. Xia D, Hsi ED, Dal Cin P, Hasserjian RP. Composite chronic myeloid leukemia and essential thrombocythemia with BCR-ABL1 fusion and CALR mutation. Am J Hematol. 2019 Apr; 94(4):504-505. PMID: 30105753.
      Citations:    
    87. Straus DJ, Jung SH, Pitcher B, Kostakoglu L, Grecula JC, Hsi ED, Schöder H, Popplewell LL, Chang JE, Moskowitz CH, Wagner-Johnston N, Leonard JP, Friedberg JW, Kahl BS, Cheson BD, Bartlett NL. CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. Blood. 2018 Sep 06; 132(10):1013-1021. PMID: 30049811.
      Citations:    
    88. Jiang YP, Liu BY, Zheng Q, Panuganti S, Chen R, Zhu J, Mishra M, Huang J, Dao-Pick T, Roy S, Zhao X, Lin J, Banik G, Hsi ED, Mandalam R, Junutula JR. CLT030, a leukemic stem cell-targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia. Blood Adv. 2018 Jul 24; 2(14):1738-1749. PMID: 30037800.
      Citations:    
    89. Shi J, Bodo J, Zhao X, Durkin L, Goyal T, Meyerson H, Hsi ED. SLAMF7 (CD319/CS1) is expressed in plasmablastic lymphoma and is a potential diagnostic marker and therapeutic target. Br J Haematol. 2019 Apr; 185(1):145-147. PMID: 29785767.
      Citations:    
    90. Aynardi J, Manur R, Hess PR, Chekol S, Morrissette JJD, Babushok D, Hexner E, Rogers HJ, Hsi ED, Margolskee E, Orazi A, Hasserjian R, Bagg A. JAK2 V617F-positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group. Br J Haematol. 2018 Jul; 182(1):78-85. PMID: 29767839.
      Citations:    
    91. Purcell JW, Tanlimco SG, Hickson J, Fox M, Sho M, Durkin L, Uziel T, Powers R, Foster K, McGonigal T, Kumar S, Samayoa J, Zhang D, Palma JP, Mishra S, Hollenbaugh D, Gish K, Morgan-Lappe SE, Hsi ED, Chao DT. LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody-Drug Conjugates. Cancer Res. 2018 Jul 15; 78(14):4059-4072. PMID: 29764866.
      Citations:    
    92. Wang X, Cao X, Sun R, Tang C, Tzankov A, Zhang J, Manyam GC, Xiao M, Miao Y, Jabbar K, Tan X, Pang Y, Visco C, Xie Y, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WWL, van Krieken JH, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Parsons BM, Winter JN, Piris MA, Li S, Miranda RN, Medeiros LJ, Li Y, Xu-Monette ZY, Young KH. Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma. Neoplasia. 2018 Jun; 20(6):574-593. PMID: 29734016.
      Citations:    
    93. Yu X, Li W, Deng Q, Li L, Hsi ED, Young KH, Zhang M, Li Y. MYD88 L265P Mutation in Lymphoid Malignancies. Cancer Res. 2018 May 15; 78(10):2457-2462. PMID: 29703722.
      Citations:    
    94. Allen J, Ruano Mendez AL, Rybicki L, Sawalha Y, Jagadeesh D, Dean R, Pohlman B, Smith MR, Hsi ED, Hill BT. Co-expression of MYC and BCL2 predicts poorer outcomes for relapsed/refractory diffuse large B-cell lymphoma with R-ICE and intent to transplant. Ther Adv Hematol. 2018 Apr; 9(4):81-87. PMID: 29623179.
      Citations:    
    95. Sakr H, Clark Schneider K, Murugesan G, Bodo J, Hsi ED, Cook JR. pSTAT3/pSTAT5 Signaling Patterns in Molecularly Defined Subsets of Myeloproliferative Neoplasms. Appl Immunohistochem Mol Morphol. 2018 Feb; 26(2):147-152. PMID: 27258562.
      Citations:    
    96. Goyal T, Thakral B, Wang SA, Bueso-Ramos CE, Shi M, Jevremovic D, Morice WG, Zhang QY, George TI, Foucar KK, Bhattacharyya S, Bagg A, Rogers HJ, Bodo J, Durkin L, Hsi ED. T-Cell Large Granular Lymphocytic Leukemia and Coexisting B-Cell Lymphomas: A Study From the Bone Marrow Pathology Group. Am J Clin Pathol. 2018 Jan 29; 149(2):164-171. PMID: 29365010.
      Citations:    
    97. Soderquist CR, Ewalt MD, Czuchlewski DR, Geyer JT, Rogers HJ, Hsi ED, Wang SA, Bueso-Ramos CE, Orazi A, Arber DA, Hexner EO, Babushok DV, Bagg A. Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group. Mod Pathol. 2018 May; 31(5):690-704. PMID: 29327708.
      Citations:    
    98. Martin P, Jung SH, Pitcher B, Bartlett NL, Blum KA, Shea T, Hsi ED, Ruan J, Smith SE, Leonard JP, Cheson BD. A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance). Ann Oncol. 2017 Nov 01; 28(11):2806-2812. PMID: 28945884.
      Citations:    
    99. Reddy A, Zhang J, Davis NS, Moffitt AB, Love CL, Waldrop A, Leppa S, Pasanen A, Meriranta L, Karjalainen-Lindsberg ML, Nørgaard P, Pedersen M, Gang AO, Høgdall E, Heavican TB, Lone W, Iqbal J, Qin Q, Li G, Kim SY, Healy J, Richards KL, Fedoriw Y, Bernal-Mizrachi L, Koff JL, Staton AD, Flowers CR, Paltiel O, Goldschmidt N, Calaminici M, Clear A, Gribben J, Nguyen E, Czader MB, Ondrejka SL, Collie A, Hsi ED, Tse E, Au-Yeung RKH, Kwong YL, Srivastava G, Choi WWL, Evens AM, Pilichowska M, Sengar M, Reddy N, Li S, Chadburn A, Gordon LI, Jaffe ES, Levy S, Rempel R, Tzeng T, Happ LE, Dave T, Rajagopalan D, Datta J, Dunson DB, Dave SS. Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma. Cell. 2017 Oct 05; 171(2):481-494.e15. PMID: 28985567.
      Citations:    
    100. Visco C, Wang J, Tisi MC, Deng L, D'Amore ESG, Tzankov A, Montes-Moreno S, Dybkær K, Bhagat G, Hsi ED, van Krieken JH, Ponzoni M, Ferreri AJM, Møller MB, Piris MA, Medeiros LJ, Xu-Monette ZY, Young KH. Hepatitis C virus positive diffuse large B-cell lymphomas have distinct molecular features and lack BCL2 translocations. Br J Cancer. 2017 Nov 21; 117(11):1685-1688. PMID: 28949959.
      Citations:    
    101. Parikh VS, Jagadeesh D, Fernandez JM, Hsi ED, Singh AD. Orbital diffuse large B-cell lymphoma with combined variable immunodeficiency. Orbit. 2017 Oct; 36(5):340-343. PMID: 28718689.
      Citations:    
    102. Mustafa Ali M, Rybicki L, Nomani L, Rouphail B, Dean RM, Hill BT, Jagadeesh D, Pohlman B, Hsi ED, Smith MR. Grade 3 Follicular Lymphoma: Outcomes in the Rituximab Era. Clin Lymphoma Myeloma Leuk. 2017 Dec; 17(12):797-803. PMID: 28789937.
      Citations:    
    103. Yao Z, Deng L, Xu-Monette ZY, Manyam GC, Jain P, Tzankov A, Visco C, Bhagat G, Wang J, Dybkaer K, Tam W, Hsi ED, van Krieken JH, Ponzoni M, Ferreri AJM, Møller MB, Winter JN, Piris MA, Fayad L, Liu Y, Song Y, Orlowski RZ, Kantarjian H, Medeiros LJ, Li Y, Cortes J, Young KH. Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy. Leukemia. 2018 Feb; 32(2):353-363. PMID: 28745330.
      Citations:    
    104. Wang J, Xu-Monette ZY, Jabbar KJ, Shen Q, Manyam GC, Tzankov A, Visco C, Wang J, Montes-Moreno S, Dybkær K, Tam W, Bhagat G, Hsi ED, van Krieken JH, Ponzoni M, Ferreri AJM, Wang S, Møller MB, Piris MA, Medeiros LJ, Li Y, Pham LV, Young KH. AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma. Am J Pathol. 2017 Aug; 187(8):1700-1716. PMID: 28627414.
      Citations:    
    105. Wang SA, Hasserjian RP, Tam W, Tsai AG, Geyer JT, George TI, Foucar K, Rogers HJ, Hsi ED, Rea BA, Bagg A, Bueso-Ramos CE, Arber DA, Verstovsek S, Orazi A. Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome. Haematologica. 2017 Aug; 102(8):1352-1360. PMID: 28495918.
      Citations:    
    106. Nakashima MO, Doyle TJ, Phelan-Lewin K, Summers JM, Bena J, Hsi ED. Assessment of semi-quantitative grading of red blood cell abnormalities utilizing images from the CellaVision DM96 compared to manual light microscopy. Int J Lab Hematol. 2017 Oct; 39(5):e110-e112. PMID: 28488791.
      Citations:    
    107. Hsi ED. 2016 WHO Classification update-What's new in lymphoid neoplasms. Int J Lab Hematol. 2017 May; 39 Suppl 1:14-22. PMID: 28447410.
      Citations:    
    108. Moffitt AB, Ondrejka SL, McKinney M, Rempel RE, Goodlad JR, Teh CH, Leppa S, Mannisto S, Kovanen PE, Tse E, Au-Yeung RKH, Kwong YL, Srivastava G, Iqbal J, Yu J, Naresh K, Villa D, Gascoyne RD, Said J, Czader MB, Chadburn A, Richards KL, Rajagopalan D, Davis NS, Smith EC, Palus BC, Tzeng TJ, Healy JA, Lugar PL, Datta J, Love C, Levy S, Dunson DB, Zhuang Y, Hsi ED, Dave SS. Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2. J Exp Med. 2017 May 01; 214(5):1371-1386. PMID: 28424246.
      Citations:    
    109. Hsi ED. A flood of information from drops of blood. Blood. 2017 Apr 06; 129(14):1891-1893. PMID: 28385769.
      Citations:    
    110. Rogers HJ, Hsi ED, Tang G, Wang SA, Bueso-Ramos CE, Lubin D, Morrissette JJ, Bagg A, Cherukuri DP, George TI, Peterson L, Liu YC, Mathew S, Orazi A, Hasserjian RP. Most Myeloid Neoplasms With Deletion of Chromosome 16q Are Distinct From Acute Myeloid Leukemia With Inv(16)(p13.1q22): A Bone Marrow Pathology Group Multicenter Study. Am J Clin Pathol. 2017 Apr 01; 147(4):411-419. PMID: 28375434.
      Citations:    
    111. Visconte V, Shetty S, Przychodzen B, Hirsch C, Bodo J, Maciejewski JP, Hsi ED, Rogers HJ. Clinicopathologic and molecular characterization of myeloid neoplasms with isolated t(6;9)(p23;q34). Int J Lab Hematol. 2017 Aug; 39(4):409-417. PMID: 28318095.
      Citations:    
    112. Cai Q, Tu M, Xu-Monette ZY, Sun R, Manyam GC, Xu X, Tzankov A, Hsi ED, Møller MB, Medeiros LJ, Ok CY, Young KH. NF-?B p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53. Mod Pathol. 2017 Jun; 30(6):854-876. PMID: 28281555.
      Citations:    
    113. Gentry M, Bodo J, Durkin L, Hsi ED. Performance of a Commercially Available MAL Antibody in the Diagnosis of Primary Mediastinal Large B-Cell Lymphoma. Am J Surg Pathol. 2017 Feb; 41(2):189-194. PMID: 27879516.
      Citations:    
    114. McKinney M, Moffitt AB, Gaulard P, Travert M, De Leval L, Nicolae A, Raffeld M, Jaffe ES, Pittaluga S, Xi L, Heavican T, Iqbal J, Belhadj K, Delfau-Larue MH, Fataccioli V, Czader MB, Lossos IS, Chapman-Fredricks JR, Richards KL, Fedoriw Y, Ondrejka SL, Hsi ED, Low L, Weisenburger D, Chan WC, Mehta-Shah N, Horwitz S, Bernal-Mizrachi L, Flowers CR, Beaven AW, Parihar M, Baseggio L, Parrens M, Moreau A, Sujobert P, Pilichowska M, Evens AM, Chadburn A, Au-Yeung RK, Srivastava G, Choi WW, Goodlad JR, Aurer I, Basic-Kinda S, Gascoyne RD, Davis NS, Li G, Zhang J, Rajagopalan D, Reddy A, Love C, Levy S, Zhuang Y, Datta J, Dunson DB, Davé SS. The Genetic Basis of Hepatosplenic T-cell Lymphoma. Cancer Discov. 2017 Apr; 7(4):369-379. PMID: 28122867.
      Citations:    
    115. Starr AG, Caimi PF, Fu P, Massoud MR, Meyerson H, Hsi ED, Mansur DB, Cherian S, Cooper BW, De Lima MJG, Lazarus HM, Gerson SL, Jagadeesh D, Smith MR, Dean RM, Pohlman BL, Hill BT, William BM. Splenic marginal zone lymphoma: excellent outcomes in 64 patients treated in the rituximab era. Hematology. 2017 Aug; 22(7):405-411. PMID: 28105889.
      Citations:    
    116. Hsi ED, Horwitz SM, Carson KR, Pinter-Brown LC, Rosen ST, Pro B, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Collie AM, Gruver AM, Grzywacz BJ, Turakhia S, Shustov AR, Advani RH, Feldman T, Lechowicz MJ, Smith SM, Lansigan F, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Park SI, Foss FM. Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States. Clin Lymphoma Myeloma Leuk. 2017 Apr; 17(4):193-200. PMID: 28209473.
      Citations:    
    117. Zhang M, Xu-Monette ZY, Li L, Manyam GC, Visco C, Tzankov A, Wang J, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Han van Krieken J, Huh J, Ponzoni M, Ferreri AJ, Møller MB, Parsons BM, Winter JN, Piris MA, Medeiros LJ, Pham LV, Young KH. RelA NF-?B subunit activation as a therapeutic target in diffuse large B-cell lymphoma. Aging (Albany NY). 2016 Dec 08; 8(12):3321-3340. PMID: 27941215.
      Citations:    
    118. Carson KR, Horwitz SM, Pinter-Brown LC, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta MA, Shustov AR, Advani RH, Feldman TA, Lechowicz MJ, Smith SM, Lansigan F, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Park SI, Foss FM. A prospective cohort study of patients with peripheral T-cell lymphoma in the United States. Cancer. 2017 Apr 01; 123(7):1174-1183. PMID: 27911989.
      Citations:    
    119. Bodo J, Zhao X, Durkin L, Souers AJ, Phillips DC, Smith MR, Hsi ED. Acquired resistance to venetoclax (ABT-199) in t(14;18) positive lymphoma cells. Oncotarget. 2016 Oct 25; 7(43):70000-70010. PMID: 27661108.
      Citations:    
    120. Xu-Monette ZY, Li L, Byrd JC, Jabbar KJ, Manyam GC, Maria de Winde C, van den Brand M, Tzankov A, Visco C, Wang J, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Huh J, Ponzoni M, Ferreri AJ, Møller MB, Parsons BM, Winter JN, Wang M, Hagemeister FB, Piris MA, Han van Krieken J, Medeiros LJ, Li Y, van Spriel AB, Young KH. Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma. Blood. 2016 Dec 29; 128(26):3083-3100. PMID: 27760757.
      Citations:    
    121. Nomani L, Bodo J, Zhao X, Durkin L, Loghavi S, Hsi ED. CAL2 Immunohistochemical Staining Accurately Identifies CALR Mutations in Myeloproliferative Neoplasms. Am J Clin Pathol. 2016 Oct; 146(4):431-8. PMID: 27686170.
      Citations:    
    122. Xia Y, Xu-Monette ZY, Tzankov A, Li X, Manyam GC, Murty V, Bhagat G, Zhang S, Pasqualucci L, Visco C, Dybkaer K, Chiu A, Orazi A, Zu Y, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Møller MB, Parsons BM, Winter JN, Piris MA, Westin J, Fowler N, Miranda RN, Ok CY, Li Y, Li J, Medeiros LJ, Young KH. Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma. Leukemia. 2017 Mar; 31(3):625-636. PMID: 27568520.
      Citations:    
    123. Starr AG, Caimi PF, Fu P, Massoud MR, Meyerson H, Hsi ED, Mansur DB, Cherian S, Cooper BW, De Lima MJ, Lazarus HM, Gerson SL, Jagadeesh D, Smith MR, Dean RM, Pohlman BL, Hill BT, William BM. Dual institution experience of nodal marginal zone lymphoma reveals excellent long-term outcomes in the rituximab era. Br J Haematol. 2016 Oct; 175(2):275-280. PMID: 27443247.
      Citations:    
    124. Caimi PF, Hill BT, Hsi ED, Smith MR. Clinical approach to diffuse large B cell lymphoma. Blood Rev. 2016 Nov; 30(6):477-491. PMID: 27596109.
      Citations:    
    125. Crump M, Leppä S, Fayad L, Lee JJ, Di Rocco A, Ogura M, Hagberg H, Schnell F, Rifkin R, Mackensen A, Offner F, Pinter-Brown L, Smith S, Tobinai K, Yeh SP, Hsi ED, Nguyen T, Shi P, Hahka-Kemppinen M, Thornton D, Lin B, Kahl B, Schmitz N, Savage KJ, Habermann T. Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2016 Jul 20; 34(21):2484-92. PMID: 27217449.
      Citations:    
    126. Wang SA, Tam W, Tsai AG, Arber DA, Hasserjian RP, Geyer JT, George TI, Czuchlewski DR, Foucar K, Rogers HJ, Hsi ED, Bryan Rea B, Bagg A, Dal Cin P, Zhao C, Kelley TW, Verstovsek S, Bueso-Ramos C, Orazi A. Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified. Mod Pathol. 2016 Aug; 29(8):854-64. PMID: 27174585.
      Citations:    
    127. Press OW, Li H, Schöder H, Straus DJ, Moskowitz CH, LeBlanc M, Rimsza LM, Bartlett NL, Evens AM, Mittra ES, LaCasce AS, Sweetenham JW, Barr PM, Fanale MA, Knopp MV, Noy A, Hsi ED, Cook JR, Lechowicz MJ, Gascoyne RD, Leonard JP, Kahl BS, Cheson BD, Fisher RI, Friedberg JW. US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. J Clin Oncol. 2016 Jun 10; 34(17):2020-7. PMID: 27069074.
      Citations:    
    128. Batlle-López A, González de Villambrosía S, Francisco M, Malatxeberria S, Sáez A, Montalban C, Sánchez L, Garcia J, González-Barca E, López-Hernández A, Ruiz-Marcellan MC, Mollejo M, Grande C, Richards KL, Hsi ED, Tzankov A, Visco C, Xu-Monette ZY, Cao X, Young KH, Piris MÁ, Conde E, Montes-Moreno S. Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker. Oncotarget. 2016 Apr 05; 7(14):18036-49. PMID: 26910115.
      Citations:    
    129. Shi Y, Zhao X, Durkin L, Rogers HJ, Hsi ED. Aberrant activation-induced cytidine deaminase expression in Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia. Hum Pathol. 2016 Jun; 52:173-8. PMID: 26980048.
      Citations:    
    130. Starr AG, Caimi PF, Fu P, Massoud MR, Meyerson H, Hsi ED, Mansur DB, Cherian S, Singh AD, Cooper BW, De Lima MJ, Lazarus HM, Gerson SL, Jagadeesh D, Smith MR, Dean RM, Pohlman BL, Hill BT, William BM. Dual institution experience of extranodal marginal zone lymphoma reveals excellent long-term outcomes. Br J Haematol. 2016 May; 173(3):404-12. PMID: 26953041.
      Citations:    
    131. Ondrejka SL, Hsi ED. T-cell Lymphomas: Updates in Biology and Diagnosis. Surg Pathol Clin. 2016 Mar; 9(1):131-41. PMID: 26940273.
      Citations:    
    132. Ondrejka SL, Grzywacz B, Bodo J, Makishima H, Polprasert C, Said JW, Przychodzen B, Maciejewski JP, Hsi ED. Angioimmunoblastic T-cell Lymphomas With the RHOA p.Gly17Val Mutation Have Classic Clinical and Pathologic Features. Am J Surg Pathol. 2016 Mar; 40(3):335-41. PMID: 26574844.
      Citations:    
    133. Xu-Monette ZY, Deng Q, Manyam GC, Tzankov A, Li L, Xia Y, Wang XX, Zou D, Visco C, Dybkær K, Li J, Zhang L, Liang H, Montes-Moreno S, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Parsons BM, Møller MB, Wang SA, Miranda RN, Piris MA, Winter JN, Medeiros LJ, Li Y, Young KH. Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma. Clin Cancer Res. 2016 Jul 15; 22(14):3593-605. PMID: 26927665.
      Citations:    
    134. Xu-Monette ZY, Zhang S, Li X, Manyam GC, Wang XX, Xia Y, Visco C, Tzankov A, Zhang L, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Zhao X, Møller MB, Parsons BM, Winter JN, Piris MA, Medeiros LJ, Young KH. p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function. Aging (Albany NY). 2016 Feb; 8(2):345-65. PMID: 26878872.
      Citations:    
    135. Ye Q, Xu-Monette ZY, Tzankov A, Deng L, Wang X, Manyam GC, Visco C, Montes-Moreno S, Zhang L, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Parsons BM, Møller MB, Piris MA, Winter JN, Medeiros LJ, Hu S, Young KH. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma. Oncotarget. 2016 Jan 19; 7(3):2401-16. PMID: 26573234.
      Citations:    
    136. King RL, Dao LN, McPhail ED, Jaffe ES, Said J, Swerdlow SH, Sattler CA, Ketterling RP, Sidhu JS, Hsi ED, Karikehalli S, Jiang L, Gibson SE, Ondrejka SL, Nicolae A, Macon WR, Dasari S, Parrilla Castellar E, Feldman AL. Morphologic Features of ALK-negative Anaplastic Large Cell Lymphomas With DUSP22 Rearrangements. Am J Surg Pathol. 2016 Jan; 40(1):36-43. PMID: 26379151.
      Citations:    
    137. Clark Schneider KM, Banks PM, Collie AM, Lanigan CP, Manilich E, Durkin LM, Hill BT, Hsi ED. Dual expression of MYC and BCL2 proteins predicts worse outcomes in diffuse large B-cell lymphoma. Leuk Lymphoma. 2016 Jul; 57(7):1640-8. PMID: 26421520.
      Citations:    
    138. Xu-Monette ZY, Dabaja BS, Wang X, Tu M, Manyam GC, Tzankov A, Xia Y, Zhang L, Sun R, Visco C, Dybkaer K, Yin L, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Møller MB, Parsons BM, Zhao X, Winter JN, Piris MA, McDonnell TJ, Miranda RN, Li Y, Medeiros LJ, Young KH. Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Mod Pathol. 2015 Dec; 28(12):1555-73. PMID: 26541272.
      Citations:    
    139. Hainsworth JD, Arrowsmith ER, McCleod M, Hsi ED, Hamid O, Shi P, Lin BK, Fayad LE. A randomized, phase 2 study of R-CHOP plus enzastaurin vs R-CHOP in patients with intermediate- or high-risk diffuse large B-cell lymphoma. Leuk Lymphoma. 2016; 57(1):216-8. PMID: 25956042.
      Citations:    
    140. Li L, Xu-Monette ZY, Ok CY, Tzankov A, Manyam GC, Sun R, Visco C, Zhang M, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Møller MB, Wang J, Parsons BM, Winter JN, Piris MA, Pham LV, Medeiros LJ, Young KH. Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma. Oncotarget. 2015 Sep 15; 6(27):23157-80. PMID: 26324762.
      Citations:    
    141. You MJ, Medeiros LJ, Hsi ED. T-lymphoblastic leukemia/lymphoma. Am J Clin Pathol. 2015 Sep; 144(3):411-22. PMID: 26276771.
      Citations:    
    142. Liu Z, Xu-Monette ZY, Cao X, Manyam GC, Wang X, Tzankov A, Xia Y, Li X, Visco C, Sun R, Zhang L, Montes-Moreno S, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Parsons BM, Møller MB, Piris MA, Winter JN, O'Malley DP, Medeiros LJ, Young KH. Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy. Mod Pathol. 2015 Oct; 28(10):1297-314. PMID: 26248897.
      Citations:    
    143. Ok CY, Xu-Monette ZY, Li L, Manyam GC, Montes-Moreno S, Tzankov A, Visco C, Dybkær K, Routbort MJ, Zhang L, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Parsons BM, Rao H, Møller MB, Winter JN, Piris MA, Wang SA, Medeiros LJ, Young KH. Evaluation of NF-?B subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions. Mod Pathol. 2015 Sep; 28(9):1202-13. PMID: 26111978.
      Citations:    
    144. Visconte V, Tabarroki A, Hasrouni E, Maciejewski JP, Hsi ED, Tiu RV, Rogers HJ. Molecular and phenotypic heterogeneity of refractory anemia with ring sideroblasts associated with marked thrombocytosis. Leuk Lymphoma. 2016; 57(1):212-5. PMID: 25926061.
      Citations:    
    145. Ok CY, Ye Q, Li L, Manyam GC, Deng L, Goswami RR, Wang X, Montes-Moreno S, Visco C, Tzankov A, Dybkaer K, Zhang L, Abramson J, Sohani AR, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Zhang S, Parsons BM, Xu M, Møller MB, Winter JN, Piris MA, Xu-Monette ZY, Medeiros LJ, Young KH. Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma--is it necessary? Oncotarget. 2015 Jun 10; 6(16):13933-45. PMID: 26101854.
      Citations:    
    146. Xu-Monette ZY, Tu M, Jabbar KJ, Cao X, Tzankov A, Visco C, Nagarajan L, Cai Q, Montes-Moreno S, An Y, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Zhao X, Møller MB, Farnen JP, Winter JN, Piris MA, Miranda RN, Medeiros LJ, Young KH. Erratum: Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries. Oncotarget. 2015 Jun 10; 6(16):14720. PMID: 26116824.
      Citations:    
    147. Zhao X, Chen-Kiang S, Shetty S, Di Liberto M, Bodo J, Durkin L, Eng K, Elemento O, Smith MR, Hsi ED. CCMCL1: a new model of aggressive mantle cell lymphoma. Blood. 2015 Apr 23; 125(17):2730-2. PMID: 25907904.
      Citations:    
    148. Jegalian AG, Bodo J, Hsi ED. NOTCH1 intracellular domain immunohistochemistry as a diagnostic tool to distinguish T-lymphoblastic lymphoma from thymoma. Am J Surg Pathol. 2015 Apr; 39(4):565-72. PMID: 25517959.
      Citations:    
    149. Wall PB, Traboulsi EI, Hsi ED, Singh AD. Bilateral conjunctival follicular lymphoma in a child. J AAPOS. 2015 Apr; 19(2):183-5. PMID: 25824110.
      Citations:    
    150. Pore D, Bodo J, Danda A, Yan D, Phillips JG, Lindner D, Hill BT, Smith MR, Hsi ED, Gupta N. Identification of Ezrin-Radixin-Moesin proteins as novel regulators of pathogenic B-cell receptor signaling and tumor growth in diffuse large B-cell lymphoma. Leukemia. 2015 Sep; 29(9):1857-67. PMID: 25801911.
      Citations:    
    151. Xu-Monette ZY, Tu M, Jabbar KJ, Cao X, Tzankov A, Visco C, Nagarajan L, Cai Q, Montes-Moreno S, An Y, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Zhao X, Møller MB, Farnen JP, Winter JN, Piris MA, Miranda RN, Medeiros LJ, Young KH. Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries. Oncotarget. 2015 Mar 20; 6(8):5615-33. PMID: 25760242.
      Citations:    
    152. Chen J, Xu-Monette ZY, Deng L, Shen Q, Manyam GC, Martinez-Lopez A, Zhang L, Montes-Moreno S, Visco C, Tzankov A, Yin L, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Zhao X, Møller MB, Farnen JP, Winter JN, Piris MA, Pham L, Young KH. Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma. Oncotarget. 2015 Mar 20; 6(8):5597-614. PMID: 25704881.
      Citations:    
    153. Choudhary GS, Al-Harbi S, Mazumder S, Hill BT, Smith MR, Bodo J, Hsi ED, Almasan A. MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies. Cell Death Dis. 2015 Jan 15; 6(1):e1593. PMID: 25590803.
      Citations:    
    154. Ondrejka SL, Hsi ED. Pathology of B-cell lymphomas: diagnosis and biomarker discovery. Cancer Treat Res. 2015; 165:27-50. PMID: 25655605.
      Citations:    
    155. Hsi ED. Update in large cell lymphoma: understanding the pathology report. Hematology Am Soc Hematol Educ Program. 2015; 2015:605-17. PMID: 26637778.
      Citations:    
    156. Visconte V, Tabarroki A, Gerace CJ, Al-Issa K, Hsi ED, Rogers HJ, Sekeres MA, Silver BJ, Lichtin AE, Mukherjee S, Tiu RV. Screening for SF3B1 mutations is a useful tool to differentiate between acquired clonal and non-clonal sideroblastic anemia. Leuk Lymphoma. 2015 Jun; 56(6):1888-90. PMID: 25330446.
      Citations:    
    157. Zhao X, Bodo J, Sun D, Durkin L, Lin J, Smith MR, Hsi ED. Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways. Br J Haematol. 2015 Mar; 168(5):765-8. PMID: 25284608.
      Citations:    
    158. Hsi ED. The SOX11-PDGFA axis in mantle cell lymphoma. Blood. 2014 Oct 02; 124(14):2165-6. PMID: 25278565.
      Citations:    
    159. Cotta CV, Hsi ED. IgG4+ plasma cells in isolated reactive lymphadenopathy. Am J Clin Pathol. 2014 Oct; 142(4):432-4. PMID: 25239407.
      Citations:    
    160. Park IJ, Bena J, Cotta CV, Hsi ED, Jegalian AG, Rogers HJ, Tubbs RR, Wang L, Cook JR. Frequency, interobserver reproducibility and clinical significance of equivocal peaks in PCR clonality testing using Euroclonality/BIOMED-2 primers. J Clin Pathol. 2014 Dec; 67(12):1093-8. PMID: 25244911.
      Citations:    
    161. Hsi ED. Flow cytometry in cerebrospinal fluid-rational use of laboratory services. Am J Hematol. 2014 Oct; 89(10):941-2. PMID: 25130189.
      Citations:    
    162. Ok CY, Chen J, Xu-Monette ZY, Tzankov A, Manyam GC, Li L, Visco C, Montes-Moreno S, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Zhao X, Ponzoni M, Ferreri AJ, Bertoni F, Farnen JP, Møller MB, Piris MA, Winter JN, Medeiros LJ, Young KH. Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma. Clin Cancer Res. 2014 Oct 01; 20(19):5113-23. PMID: 25124685.
      Citations:    
    163. Hasserjian RP, Campigotto F, Klepeis V, Fu B, Wang SA, Bueso-Ramos C, Cascio MJ, Rogers HJ, Hsi ED, Soderquist C, Bagg A, Yan J, Ochs R, Orazi A, Moore F, Mahmoud A, George TI, Foucar K, Odem J, Booth C, Morice W, DeAngelo DJ, Steensma D, Stone RM, Neuberg D, Arber DA. De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with =30% blasts in older adults: a Bone Marrow Pathology Group study. Am J Hematol. 2014 Nov; 89(11):E193-9. PMID: 25042343.
      Citations:    
    164. Collie AM, Nölling J, Divakar KM, Lin JJ, Carver P, Durkin LM, Hill BT, Smith MR, Radivoyevitch T, Kong LI, Daly T, Murugesan G, Guenther-Johnson J, Dave SS, Manilich EA, Hsi ED. Molecular subtype classification of formalin-fixed, paraffin-embedded diffuse large B-cell lymphoma samples on the ICEPlex® system. Br J Haematol. 2014 Oct; 167(2):281-5. PMID: 24961756.
      Citations:    
    165. Ondrejka SL, Jegalian AG, Kim AS, Chabot-Richards DS, Giltnane J, Czuchlewski DR, Shetty S, Sekeres MA, Yenamandra A, Head D, Jagasia M, Hsi ED. PDGFRB-rearranged T-lymphoblastic leukemia/lymphoma occurring with myeloid neoplasms: the missing link supporting a stem cell origin. Haematologica. 2014 Sep; 99(9):e148-51. PMID: 24951465.
      Citations:    
    166. Parrilla Castellar ER, Jaffe ES, Said JW, Swerdlow SH, Ketterling RP, Knudson RA, Sidhu JS, Hsi ED, Karikehalli S, Jiang L, Vasmatzis G, Gibson SE, Ondrejka S, Nicolae A, Grogg KL, Allmer C, Ristow KM, Wilson WH, Macon WR, Law ME, Cerhan JR, Habermann TM, Ansell SM, Dogan A, Maurer MJ, Feldman AL. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood. 2014 Aug 28; 124(9):1473-80. PMID: 24894770.
      Citations:    
    167. Hsi ED, Said J, Macon WR, Rodig SJ, Ondrejka SL, Gascoyne RD, Morgan EA, Dorfman DM, Maurer MJ, Dogan A. Diagnostic accuracy of a defined immunophenotypic and molecular genetic approach for peripheral T/NK-cell lymphomas. A North American PTCL study group project. Am J Surg Pathol. 2014 Jun; 38(6):768-75. PMID: 24618604.
      Citations:    
    168. Kurtovic-Kozaric A, Przychodzen B, Singh J, Konarska MM, Clemente MJ, Otrock ZK, Nakashima M, Hsi ED, Yoshida K, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Ogawa S, Boultwood J, Makishima H, Maciejewski JP, Padgett RA. PRPF8 defects cause missplicing in myeloid malignancies. Leukemia. 2015 Jan; 29(1):126-36. PMID: 24781015.
      Citations:    
    169. Collie AM, Hill BT, Stevens GH, Fenner K, Gazdick E, Hsi ED. Flow cytometric analysis of cerebrospinal fluid has low diagnostic yield in samples without atypical morphology or prior history of hematologic malignancy. Am J Clin Pathol. 2014 Apr; 141(4):515-21. PMID: 24619752.
      Citations:    
    170. Zhang J, Jima D, Moffitt AB, Liu Q, Czader M, Hsi ED, Fedoriw Y, Dunphy CH, Richards KL, Gill JI, Sun Z, Love C, Scotland P, Lock E, Levy S, Hsu DS, Dunson D, Dave SS. The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells. Blood. 2014 May 08; 123(19):2988-96. PMID: 24682267.
      Citations:    
    171. Schwartzberg L, Hermann R, Flinn I, Flora D, Hsi ED, Hamid O, Shi P, Lin BK, Myrand SP, Nguyen TS, Dreyling M. Open-label, single-arm, phase II study of enzastaurin in patients with follicular lymphoma. Br J Haematol. 2014 Jul; 166(1):91-7. PMID: 24673609.
      Citations:    
    172. Ok CY, Xu-Monette ZY, Tzankov A, O'Malley DP, Montes-Moreno S, Visco C, Møller MB, Dybkaer K, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Han van Krieken J, Ponzoni M, Farnen JP, Piris MA, Winter JN, Medeiros LJ, Young KH. Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. Cancer. 2014 Jun 15; 120(12):1818-29. PMID: 24648050.
      Citations:    
    173. Wang SA, Hasserjian RP, Fox PS, Rogers HJ, Geyer JT, Chabot-Richards D, Weinzierl E, Hatem J, Jaso J, Kanagal-Shamanna R, Stingo FC, Patel KP, Mehrotra M, Bueso-Ramos C, Young KH, Dinardo CD, Verstovsek S, Tiu RV, Bagg A, Hsi ED, Arber DA, Foucar K, Luthra R, Orazi A. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood. 2014 Apr 24; 123(17):2645-51. PMID: 24627528.
      Citations:    
    174. Ok CY, Li L, Xu-Monette ZY, Visco C, Tzankov A, Manyam GC, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Chen J, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ai W, Ponzoni M, Ferreri AJ, Farnen JP, Møller MB, Bueso-Ramos CE, Miranda RN, Winter JN, Piris MA, Medeiros LJ, Young KH. Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries. Clin Cancer Res. 2014 May 01; 20(9):2338-49. PMID: 24583797.
      Citations:    
    175. Rogers HJ, Vardiman JW, Anastasi J, Raca G, Savage NM, Cherry AM, Arber D, Moore E, Morrissette JJ, Bagg A, Liu YC, Mathew S, Orazi A, Lin P, Wang SA, Bueso-Ramos CE, Foucar K, Hasserjian RP, Tiu RV, Karafa M, Hsi ED. Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study. Haematologica. 2014 May; 99(5):821-9. PMID: 24463215.
      Citations:    
    176. Hsi ED. Undiagnosed mycosis fungoides with transformation to large cell peripheral T-cell lymphoma. Clin Adv Hematol Oncol. 2014 Jan; 12 Suppl 2(1):6-11. PMID: 25855892.
      Citations:    
    177. Hsi ED. Undiagnosed mycosis fungoides with transformation to large cell peripheral T-cell lymphoma. Clin Adv Hematol Oncol. 2014 Jan; 12(1 Suppl 2):6-11. PMID: 24852618.
      Citations:    
    178. Nakashima MO, Durkin L, Bodo J, Lin J, Quintanilla-Martinez L, Fu K, Hsi ED. Utility and diagnostic pitfalls of SOX11 monoclonal antibodies in mantle cell lymphoma and other lymphoproliferative disorders. Appl Immunohistochem Mol Morphol. 2014; 22(10):720-7. PMID: 25229384.
      Citations:    
    179. Tzankov A, Xu-Monette ZY, Gerhard M, Visco C, Dirnhofer S, Gisin N, Dybkaer K, Orazi A, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Ponzoni M, Ferreri AJ, Ye Q, Winter JN, Farnen JP, Piris MA, Møller MB, You MJ, McDonnell T, Medeiros LJ, Young KH. Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Mod Pathol. 2014 Jul; 27(7):958-71. PMID: 24336156.
      Citations:    
    180. Rogers HJ, Hsi ED. Myeloid Neoplasms with inv(3)(q21q26.2) or t(3;3)(q21;q26.2). Surg Pathol Clin. 2013 Dec; 6(4):677-92. PMID: 26839193.
      Citations:    
    181. Hsi ED, Martin P. Indolent mantle cell lymphoma. Leuk Lymphoma. 2014 Apr; 55(4):761-7. PMID: 23927395.
      Citations:    
    182. Liu L, Perry AM, Cao W, Smith LM, Hsi ED, Liu X, Mo JQ, Dotlic S, Mosunjac M, Talmon G, Weisenburger DD, Fu K. Relationship between Rosai-Dorfman disease and IgG4-related disease: study of 32 cases. Am J Clin Pathol. 2013 Sep; 140(3):395-402. PMID: 23955459.
      Citations:    
    183. Ondrejka SL, Lin JJ, Warden DW, Durkin L, Cook JR, Hsi ED. MYD88 L265P somatic mutation: its usefulness in the differential diagnosis of bone marrow involvement by B-cell lymphoproliferative disorders. Am J Clin Pathol. 2013 Sep; 140(3):387-94. PMID: 23955458.
      Citations:    
    184. Smith LB, Hsi ED. Lymphomas of the Gastrointestinal Tract: An Update. Surg Pathol Clin. 2013 Sep; 6(3):405-24. PMID: 26839095.
      Citations:    
    185. Xu-Monette ZY, Møller MB, Tzankov A, Montes-Moreno S, Hu W, Manyam GC, Kristensen L, Fan L, Visco C, Dybkaer K, Chiu A, Tam W, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huang Q, Huh J, Ai W, Ponzoni M, Ferreri AJ, Wu L, Zhao X, Bueso-Ramos CE, Wang SA, Go RS, Li Y, Winter JN, Piris MA, Medeiros LJ, Young KH. MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013 Oct 10; 122(15):2630-40. PMID: 23982177.
      Citations:    
    186. Deng L, Xu-Monette ZY, Loghavi S, Manyam GC, Xia Y, Visco C, Huh J, Zhang L, Zhai Q, Wang Y, Qiu L, Dybkær K, Chiu A, Perry AM, Zhang S, Tzankov A, Rao H, Abramson J, Sohani AR, Xu M, Hsi ED, Zhu J, Ponzoni M, Wang S, Li L, Zhang M, Ferreri AJ, Parsons BM, Li Y, Piris MA, Medeiros LJ, Young KH. Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium. Leukemia. 2016 Feb; 30(2):361-72. PMID: 26308769.
      Citations:    
    187. Karai LJ, Kadin ME, Hsi ED, Sluzevich JC, Ketterling RP, Knudson RA, Feldman AL. Chromosomal rearrangements of 6p25.3 define a new subtype of lymphomatoid papulosis. Am J Surg Pathol. 2013 Aug; 37(8):1173-81. PMID: 23648461.
      Citations:    
    188. Bodo J, Zhao X, Sharma A, Hill BT, Portell CA, Lannutti BJ, Almasan A, Hsi ED. The phosphatidylinositol 3-kinases (PI3K) inhibitor GS-1101 synergistically potentiates histone deacetylase inhibitor-induced proliferation inhibition and apoptosis through the inactivation of PI3K and extracellular signal-regulated kinase pathways. Br J Haematol. 2013 Oct; 163(1):72-80. PMID: 23889282.
      Citations:    
    189. Frei E, Visco C, Xu-Monette ZY, Dirnhofer S, Dybkær K, Orazi A, Bhagat G, Hsi ED, van Krieken JH, Ponzoni M, Go RS, Piris MA, Møller MB, Young KH, Tzankov A. Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma. J Clin Pathol. 2013 Nov; 66(11):956-61. PMID: 23775435.
      Citations:    
    190. Chamsi-Pasha MA, Alraies MC, Alraiyes AH, Hsi ED. Mycobacterium avium Complex-Associated Hemophagocytic Lymphohistiocytosis in a Sickle Cell Patient: An Unusual Fatal Association. Case Rep Hematol. 2013; 2013:291518. PMID: 23762672.
      Citations:    
    191. Rubenstein JL, Hsi ED, Johnson JL, Jung SH, Nakashima MO, Grant B, Cheson BD, Kaplan LD. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol. 2013 Sep 01; 31(25):3061-8. PMID: 23569323.
      Citations:    
    192. Pagni F, Bosisio FM, Sala E, Cattoretti G, Isimbaldi G, Coppola S, Nespoli L, Carpenedo M, Hsi ED, Dogan A. The plasmablasts in Castleman disease. Am J Clin Pathol. 2013 Apr; 139(4):555-9. PMID: 23525622.
      Citations:    
    193. Hsi ED, Dogan A. The authors' reply. Am J Clin Pathol. 2013 Apr; 139(4):559. PMID: 23634454.
      Citations:    
    194. Li Y, Gordon MW, Xu-Monette ZY, Visco C, Tzankov A, Zou D, Qiu L, Montes-Moreno S, Dybkaer K, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huang Q, Ai W, Ponzoni M, Ferreri AJ, Winter JN, Go RS, Piris MA, Møller MB, Wu L, Wang M, Ramos KS, Medeiros LJ, Young KH. Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013 May 30; 121(22):4529-40. PMID: 23515929.
      Citations:    
    195. Hu S, Xu-Monette ZY, Tzankov A, Green T, Wu L, Balasubramanyam A, Liu WM, Visco C, Li Y, Miranda RN, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Zhao X, van Krieken JH, Huang Q, Huh J, Ai W, Ponzoni M, Ferreri AJ, Zhou F, Slack GW, Gascoyne RD, Tu M, Variakojis D, Chen W, Go RS, Piris MA, Møller MB, Medeiros LJ, Young KH. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013 May 16; 121(20):4021-31; quiz 4250. PMID: 23449635.
      Citations:    
    196. Warden DW, Ondrejka S, Lin J, Durkin L, Bodo J, Hsi ED. Phospho-ERK(THR202/Tyr214) is overexpressed in hairy cell leukemia and is a useful diagnostic marker in bone marrow trephine sections. Am J Surg Pathol. 2013 Feb; 37(2):305-8. PMID: 23211289.
      Citations:    
    197. Hu S, Xu-Monette ZY, Balasubramanyam A, Manyam GC, Visco C, Tzankov A, Liu WM, Miranda RN, Zhang L, Montes-Moreno S, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Han van Krieken J, Huang Q, Huh J, Ai W, Ponzoni M, Ferreri AJ, Zhao X, Winter JN, Zhang M, Li L, Møller MB, Piris MA, Li Y, Go RS, Wu L, Medeiros LJ, Young KH. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2013 Apr 04; 121(14):2715-24. PMID: 23343832.
      Citations:    
    198. Zhang J, Grubor V, Love CL, Banerjee A, Richards KL, Mieczkowski PA, Dunphy C, Choi W, Au WY, Srivastava G, Lugar PL, Rizzieri DA, Lagoo AS, Bernal-Mizrachi L, Mann KP, Flowers C, Naresh K, Evens A, Gordon LI, Czader M, Gill JI, Hsi ED, Liu Q, Fan A, Walsh K, Jima D, Smith LL, Johnson AJ, Byrd JC, Luftig MA, Ni T, Zhu J, Chadburn A, Levy S, Dunson D, Dave SS. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A. 2013 Jan 22; 110(4):1398-403. PMID: 23292937.
      Citations:    
    199. Love C, Sun Z, Jima D, Li G, Zhang J, Miles R, Richards KL, Dunphy CH, Choi WW, Srivastava G, Lugar PL, Rizzieri DA, Lagoo AS, Bernal-Mizrachi L, Mann KP, Flowers CR, Naresh KN, Evens AM, Chadburn A, Gordon LI, Czader MB, Gill JI, Hsi ED, Greenough A, Moffitt AB, McKinney M, Banerjee A, Grubor V, Levy S, Dunson DB, Dave SS. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet. 2012 Dec; 44(12):1321-5. PMID: 23143597.
      Citations:    
    200. Chao DT, Su M, Tanlimco S, Sho M, Choi D, Fox M, Ye S, Hsi ED, Durkin L, Yin J, Zhang Y, Kim H, Starling GC, Culp PA. Expression of TweakR in breast cancer and preclinical activity of enavatuzumab, a humanized anti-TweakR mAb. J Cancer Res Clin Oncol. 2013 Feb; 139(2):315-25. PMID: 23073510.
      Citations:    
    201. Gruver AM, Huba MA, Dogan A, Hsi ED. Fibrin-associated large B-cell lymphoma: part of the spectrum of cardiac lymphomas. Am J Surg Pathol. 2012 Oct; 36(10):1527-37. PMID: 22982895.
      Citations:    
    202. Xu-Monette ZY, Wu L, Visco C, Tai YC, Tzankov A, Liu WM, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Zhao XF, Choi WW, Zhao X, van Krieken JH, Huang Q, Huh J, Ai W, Ponzoni M, Ferreri AJ, Zhou F, Kahl BS, Winter JN, Xu W, Li J, Go RS, Li Y, Piris MA, Møller MB, Miranda RN, Abruzzo LV, Medeiros LJ, Young KH. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2012 Nov 08; 120(19):3986-96. PMID: 22955915.
      Citations:    
    203. Jerez A, Clemente MJ, Makishima H, Koskela H, Leblanc F, Peng Ng K, Olson T, Przychodzen B, Afable M, Gomez-Segui I, Guinta K, Durkin L, Hsi ED, McGraw K, Zhang D, Wlodarski MW, Porkka K, Sekeres MA, List A, Mustjoki S, Loughran TP, Maciejewski JP. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood. 2012 Oct 11; 120(15):3048-57. PMID: 22859607.
      Citations:    
    204. Zhang J, Grubor V, Love CL, Banerjee A, Richards KL, Miezcowski P, Dunphy CH, Choi WWL, Auv WY, Srivastava G, Lugar PL, Rizzieri DA, Lagoo AS, Bernal-Mizrachi L, Mann KP, Flowers CR, Naresh KN, Evens AM, Gordon LI, Czader MB, Gill JI, Hsi ED, Liu Q, Fan A, Walsh K, Jima DD, Luftig M, Ni T, Zhu J, Chadburn A, Levy S, Dunson DB, Dave SS. 13th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI) Bethesda, MD, USA. 7-8 November 2011. Abstracts. Infect Agent Cancer. 2012 Apr 19; 7 Suppl 1(Suppl 1):O1-P49. PMID: 22551362.
      Citations:    
    205. Visco C, Li Y, Xu-Monette ZY, Miranda RN, Green TM, Li Y, Tzankov A, Wen W, Liu WM, Kahl BS, d'Amore ES, Montes-Moreno S, Dybkær K, Chiu A, Tam W, Orazi A, Zu Y, Bhagat G, Winter JN, Wang HY, O'Neill S, Dunphy CH, Hsi ED, Zhao XF, Go RS, Choi WW, Zhou F, Czader M, Tong J, Zhao X, van Krieken JH, Huang Q, Ai W, Etzell J, Ponzoni M, Ferreri AJ, Piris MA, Møller MB, Bueso-Ramos CE, Medeiros LJ, Wu L, Young KH. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia. 2012 Sep; 26(9):2103-13. PMID: 22437443.
      Citations:    
    206. Czuczman MS, Leonard JP, Jung S, Johnson JL, Hsi ED, Byrd JC, Cheson BD. Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness. Ann Oncol. 2012 Sep; 23(9):2356-2362. PMID: 22357442.
      Citations:    
    207. Hsi ED. Pathologic and molecular genetic features of chronic lymphocytic leukemia. Semin Oncol. 2012 Feb; 39(1):74-9. PMID: 22289494.
      Citations:    
    208. Zeng W, Fu K, Quintanilla-Fend L, Lim M, Ondrejka S, Hsi ED. Cyclin D1-negative blastoid mantle cell lymphoma identified by SOX11 expression. Am J Surg Pathol. 2012 Feb; 36(2):214-9. PMID: 22251940.
      Citations:    
    209. Cotta CV, Coleman JF, Li S, Hsi ED. Nodular lymphocyte predominant Hodgkin lymphoma and diffuse large B-cell lymphoma: a study of six cases concurrently involving the same site. Histopathology. 2011 Dec; 59(6):1194-203. PMID: 22175899.
      Citations:    
    210. Wilson WH, Jung SH, Porcu P, Hurd D, Johnson J, Martin SE, Czuczman M, Lai R, Said J, Chadburn A, Jones D, Dunleavy K, Canellos G, Zelenetz AD, Cheson BD, Hsi ED. A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica. 2012 May; 97(5):758-65. PMID: 22133772.
      Citations:    
    211. Liu H, Johnson JL, Koval G, Malnassy G, Sher D, Damon LE, Hsi ED, Bucci DM, Linker CA, Cheson BD, Stock W. Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909. Haematologica. 2012 Apr; 97(4):579-85. PMID: 22102709.
      Citations:    
    212. Bodo J, Sedlak J, Maciejewski JP, Almasan A, Hsi ED. HDAC inhibitors potentiate the apoptotic effect of enzastaurin in lymphoma cells. Apoptosis. 2011 Sep; 16(9):914-23. PMID: 21667043.
      Citations:    
    213. Clemente MJ, Wlodarski MW, Makishima H, Viny AD, Bretschneider I, Shaik M, Bejanyan N, Lichtin AE, Hsi ED, Paquette RL, Loughran TP, Maciejewski JP. Clonal drift demonstrates unexpected dynamics of the T-cell repertoire in T-large granular lymphocyte leukemia. Blood. 2011 Oct 20; 118(16):4384-93. PMID: 21865345.
      Citations:    
    214. Jankowska AM, Makishima H, Tiu RV, Szpurka H, Huang Y, Traina F, Visconte V, Sugimoto Y, Prince C, O'Keefe C, Hsi ED, List A, Sekeres MA, Rao A, McDevitt MA, Maciejewski JP. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood. 2011 Oct 06; 118(14):3932-41. PMID: 21828135.
      Citations:    
    215. Horwitz SM, Coiffier B, Hsi ED, Pro B. Current treatment of peripheral T-cell lymphoma. Clin Adv Hematol Oncol. 2011 Aug; 9(8 Suppl 16):1-15. PMID: 22361915.
      Citations:    
    216. Hsi ED, Lorsbach RB, Fend F, Dogan A. Plasmablastic lymphoma and related disorders. Am J Clin Pathol. 2011 Aug; 136(2):183-94. PMID: 21757592.
      Citations:    
    217. Lorsbach RB, Hsi ED, Dogan A, Fend F. Plasma cell myeloma and related neoplasms. Am J Clin Pathol. 2011 Aug; 136(2):168-82. PMID: 21757591.
      Citations:    
    218. Bodo J, Hsi ED. Phosphoproteins and the dawn of functional phenotyping. Pathobiology. 2011; 78(2):115-21. PMID: 21677474.
      Citations:    
    219. Montes-Moreno S, Martinez N, Sanchez-Espiridión B, Díaz Uriarte R, Rodriguez ME, Saez A, Montalbán C, Gomez G, Pisano DG, García JF, Conde E, Gonzalez-Barca E, Lopez A, Mollejo M, Grande C, Martinez MA, Dunphy C, Hsi ED, Rocque GB, Chang J, Go RS, Visco C, Xu-Monette Z, Young KH, Piris MA. miRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy. Blood. 2011 Jul 28; 118(4):1034-40. PMID: 21633089.
      Citations:    
    220. Rimm DL, Nielsen TO, Jewell SD, Rohrer DC, Broadwater G, Waldman F, Mitchell KA, Singh B, Tsongalis GJ, Frankel WL, Magliocco AM, Lara JF, Hsi ED, Bleiweiss IJ, Badve SS, Chen B, Ravdin PM, Schilsky RL, Thor A, Berry DA. Cancer and Leukemia Group B Pathology Committee guidelines for tissue microarray construction representing multicenter prospective clinical trial tissues. J Clin Oncol. 2011 Jun 01; 29(16):2282-90. PMID: 21519016.
      Citations:    
    221. Ondrejka SL, Lai R, Smith SD, Hsi ED. Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis. Haematologica. 2011 Aug; 96(8):1121-7. PMID: 21508124.
      Citations:    
    222. Bencsath KP, Reu F, Dietz J, Hsi ED, Heresi GA. Idiopathic systemic capillary leak syndrome preceding diagnosis of infiltrating lobular carcinoma of the breast with quiescence during neoadjuvant chemotherapy. Mayo Clin Proc. 2011 Mar; 86(3):260-1. PMID: 21364118.
      Citations:    
    223. Straus DJ, Johnson JL, LaCasce AS, Bartlett NL, Kostakoglu L, Hsi ED, Schöder H, Hall NC, Jung SH, Canellos GP, Schwartz LH, Takvorian RW, Juweid ME, Cheson BD. Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. Blood. 2011 May 19; 117(20):5314-20. PMID: 21355087.
      Citations:    
    224. Richendollar BG, Pohlman B, Elson P, Hsi ED. Follicular programmed death 1-positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma. Hum Pathol. 2011 Apr; 42(4):552-7. PMID: 21237493.
      Citations:    
    225. Duong HK, Bolwell BJ, Rybicki L, Koo A, Hsi ED, Figueroa P, Dean R, Pohlman B, Kalaycio M, Andresen S, Sobecks R, Copelan E. Predicting hematopoietic stem cell mobilization failure in patients with multiple myeloma: a simple method using day 1 CD34+ cell yield. J Clin Apher. 2011; 26(3):111-5. PMID: 21647951.
      Citations:    
    226. Bodo J, Hsi ED. Selection and validation of antibodies for signal transduction immunohistochemistry. Methods Mol Biol. 2011; 717:45-53. PMID: 21370023.
      Citations:    
    227. Wada DA, Law ME, Hsi ED, Dicaudo DJ, Ma L, Lim MS, Souza Ad, Comfere NI, Weenig RH, Macon WR, Erickson LA, Ozsan N, Ansell SM, Dogan A, Feldman AL. Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies. Mod Pathol. 2011 Apr; 24(4):596-605. PMID: 21169992.
      Citations:    
    228. Horwitz SM, Duvic M, Hsi ED. Clinical roundtable monograph. The management of aggressive T-cell lymphoma: a discussion on transformed mycosis fungoides. Clin Adv Hematol Oncol. 2010 Dec; 8(12):1-15. PMID: 21344783.
      Citations:    
    229. Armitage JO, Hsi ED, Foss FM. Clinical roundtable monograph. T-cell lymphoma: therapeutic overview and disease state awareness. Clin Adv Hematol Oncol. 2010 Dec; 8(12 Suppl 22):1-15. PMID: 21491667.
      Citations:    
    230. Hsi ED, Tadmor T. Microenvironment in peripheral T cell lymphomas: macrophages and angiogenesis as targets. Leuk Lymphoma. 2011 Jan; 52(1):3-4. PMID: 21067439.
      Citations:    
    231. Advani AS, Gibson SE, Douglas E, Jin T, Zhao X, Kalaycio M, Copelan E, Sobecks R, Sekeres M, Sungren S, Hsi ED. Histone H4 acetylation by immunohistochemistry and prognosis in newly diagnosed adult acute lymphoblastic leukemia (ALL) patients. BMC Cancer. 2010 Jul 21; 10:387. PMID: 20663136.
      Citations:    
    232. Hussong JW, Arber DA, Bradley KT, Brown MS, Chang CC, de Baca ME, Ellis DW, Foucar K, Hsi ED, Jaffe ES, Lill M, McClure SP, Medeiros LJ, Perkins SL. Protocol for the examination of specimens from patients with non-Hodgkin lymphoma/lymphoid neoplasms. Arch Pathol Lab Med. 2010 Jun; 134(6):e40-7. PMID: 20524855.
      Citations:    
    233. Howard MT, Bejanyan N, Maciejewski JP, Hsi ED. T/NK large granular lymphocyte leukemia and coexisting monoclonal B-cell lymphocytosis-like proliferations. An unrecognized and frequent association. Am J Clin Pathol. 2010 Jun; 133(6):936-41. PMID: 20472852.
      Citations:    
    234. Blum KA, Jung SH, Johnson JL, Lin TS, Hsi ED, Lucas DM, Byrd JC, Cheson BD, Bartlett NL. Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an Fc?RIIIa-158 V/F polymorphism. Ann Oncol. 2010 Nov; 21(11):2246-2254. PMID: 20423913.
      Citations:    
    235. Hansel DE, Platt E, Orloff M, Harwalker J, Sethu S, Hicks JL, De Marzo A, Steinle RE, Hsi ED, Theodorescu D, Ching CB, Eng C. Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma. Am J Pathol. 2010 Jun; 176(6):3062-72. PMID: 20395440.
      Citations:    
    236. Winter JN, Li S, Aurora V, Variakojis D, Nelson B, Krajewska M, Zhang L, Habermann TM, Fisher RI, Macon WR, Chhanabhai M, Felgar RE, Hsi ED, Medeiros LJ, Weick JK, Weller EA, Melnick A, Reed JC, Horning SJ, Gascoyne RD. Expression of p21 protein predicts clinical outcome in DLBCL patients older than 60 years treated with R-CHOP but not CHOP: a prospective ECOG and Southwest Oncology Group correlative study on E4494. Clin Cancer Res. 2010 Apr 15; 16(8):2435-42. PMID: 20371683.
      Citations:    
    237. Szpurka H, Jankowska AM, Makishima H, Bodo J, Bejanyan N, Hsi ED, Sekeres MA, Maciejewski JP. Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutations. Leuk Res. 2010 Aug; 34(8):969-73. PMID: 20334914.
      Citations:    
    238. Bradley KT, Arber DA, Brown MS, Chang CC, Coupland SE, de Baca ME, Ellis DW, Foucar K, Hsi ED, Jaffe ES, Lill MC, McClure SP, Medeiros LJ, Perkins SL, Hussong JW. Protocol for the examination of specimens from patients with hematopoietic neoplasms of the ocular adnexa. Arch Pathol Lab Med. 2010 Mar; 134(3):336-40. PMID: 20196660.
      Citations:    
    239. Weaver J, Mahindra AK, Pohlman B, Jin T, Hsi ED. Non-mycosis fungoides cutaneous T-cell lymphoma: reclassification according to the WHO-EORTC classification. J Cutan Pathol. 2010 May; 37(5):516-24. PMID: 20132421.
      Citations:    
    240. Culp PA, Choi D, Zhang Y, Yin J, Seto P, Ybarra SE, Su M, Sho M, Steinle R, Wong MH, Evangelista F, Grove J, Cardenas M, James M, Hsi ED, Chao DT, Powers DB, Ramakrishnan V, Dubridge R. Antibodies to TWEAK receptor inhibit human tumor growth through dual mechanisms. Clin Cancer Res. 2010 Jan 15; 16(2):497-508. PMID: 20068083.
      Citations:    
    241. Quintanilla-Martinez L, de Jong D, de Mascarel A, Hsi ED, Kluin P, Natkunam Y, Parrens M, Pileri S, Ott G. Gray zones around diffuse large B cell lymphoma. Conclusions based on the workshop of the XIV meeting of the European Association for Hematopathology and the Society of Hematopathology in Bordeaux, France. J Hematop. 2009 Dec 22; 2(4):211-36. PMID: 20309430.
      Citations:    
    242. Richendollar BG, Tsao RE, Elson P, Jin T, Steinle R, Pohlman B, Hsi ED. Predictors of outcome in post-transplant lymphoproliferative disorder: an evaluation of tumor infiltrating lymphocytes in the context of clinical factors. Leuk Lymphoma. 2009 Dec; 50(12):2005-12. PMID: 19860626.
      Citations:    
    243. Sweetenham JW, Goldman B, LeBlanc ML, Cook JR, Tubbs RR, Press OW, Maloney DG, Fisher RI, Rimsza LM, Braziel RM, Hsi ED. Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study. Ann Oncol. 2010 Jun; 21(6):1196-1202. PMID: 19875761.
      Citations:    
    244. Richendollar BG, Hsi ED, Cook JR. Extramedullary plasmacytoma-like posttransplantation lymphoproliferative disorders: clinical and pathologic features. Am J Clin Pathol. 2009 Oct; 132(4):581-8. PMID: 19762536.
      Citations:    
    245. Smith SD, Bolwell BJ, Advani AS, Andresen SW, Chan JL, Dean RM, Hsi ED, Kalaycio ME, Pohlman BL, Rybicki LA, Sweetenham JW. High rate of survival in transformed lymphoma after autologous stem cell transplant: pathologic analysis and comparison with de novo diffuse large B-cell lymphoma. Leuk Lymphoma. 2009 Oct; 50(10):1625-31. PMID: 19672775.
      Citations:    
    246. Miles RR, Mankey CC, Seiler CE, Smith LB, Teruya-Feldstein J, Hsi ED, Elenitoba-Johnson KS, Lim MS. Expression of Grb2 distinguishes classical Hodgkin lymphomas from primary mediastinal B-cell lymphomas and other diffuse large B-cell lymphomas. Hum Pathol. 2009 Dec; 40(12):1731-7. PMID: 19716163.
      Citations:    
    247. Hsi ED. The leukemias of mature lymphocytes. Hematol Oncol Clin North Am. 2009 Aug; 23(4):843-71. PMID: 19577172.
      Citations:    
    248. Zhao X, Singh S, Pardoux C, Zhao J, Hsi ED, Abo A, Korver W. Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia. Haematologica. 2010 Jan; 95(1):71-8. PMID: 19648166.
      Citations:    
    249. Quintanilla-Martinez L, Slotta-Huspenina J, Koch I, Klier M, Hsi ED, de Leval L, Klapper W, Gesk S, Siebert R, Fend F. Differential diagnosis of cyclin D2+ mantle cell lymphoma based on fluorescence in situ hybridization and quantitative real-time-PCR. Haematologica. 2009 Nov; 94(11):1595-8. PMID: 19608671.
      Citations:    
    250. Lee MC, Aron M, Hsi ED, Herts BR, Pohlman B, Gill IS. Age-related Epstein-Barr virus-associated lymphoproliferative disorder presenting as renal mass. Urology. 2009 Sep; 74(3):505-8. PMID: 19592072.
      Citations:    
    251. Korver W, Zhao X, Singh S, Pardoux C, Zhao J, Guzman ML, Sen S, Yonkovich S, Liu S, Zhan X, Tomasevic N, Zhou C, Gros D, Jordan CT, Gotlib J, Hsi ED, Abo A. Monoclonal antibodies against IREM-1: potential for targeted therapy of AML. Leukemia. 2009 Sep; 23(9):1587-97. PMID: 19440216.
      Citations:    
    252. Hsi ED. The role of biomarkers in the management of patients with lymphoma: promise versus reality. Clin Lymphoma Myeloma. 2009 Apr; 9(2):121-3. PMID: 19406721.
      Citations:    
    253. Bodo J, Durkin L, Hsi ED. Quantitative in situ detection of phosphoproteins in fixed tissues using quantum dot technology. J Histochem Cytochem. 2009 Jul; 57(7):701-8. PMID: 19332430.
      Citations:    
    254. Hsi ED. T-cell lymphoma in the head and neck? Think about adult T-cell leukemia/lymphoma. Leuk Lymphoma. 2009 Feb; 50(2):150-1. PMID: 19235010.
      Citations:    
    255. Gibson SE, Hsi ED. Epstein-Barr virus-positive B-cell lymphoma of the elderly at a United States tertiary medical center: an uncommon aggressive lymphoma with a nongerminal center B-cell phenotype. Hum Pathol. 2009 May; 40(5):653-61. PMID: 19144386.
      Citations:    
    256. Cotta CV, Hsi ED. Pathobiology of mature T-cell lymphomas. Clin Lymphoma Myeloma. 2008 Dec; 8 Suppl 5:S168-79. PMID: 19073524.
      Citations:    
    257. Hsi ED, Jung SH, Lai R, Johnson JL, Cook JR, Jones D, Devos S, Cheson BD, Damon LE, Said J. Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study. Leuk Lymphoma. 2008 Nov; 49(11):2081-90. PMID: 19021050.
      Citations:    
    258. Weaver J, Hsi ED. CD4+/CD56+ hematodermic neoplasm (blastic NK-cell lymphoma). J Cutan Pathol. 2008 Oct; 35(10):975-7. PMID: 18822062.
      Citations:    
    259. Szpurka H, Gondek LP, Mohan SR, Hsi ED, Theil KS, Maciejewski JP. UPD1p indicates the presence of MPL W515L mutation in RARS-T, a mechanism analogous to UPD9p and JAK2 V617F mutation. Leukemia. 2009 Mar; 23(3):610-4. PMID: 18818701.
      Citations:    
    260. Hsi ED. Biologic features of Hodgkin lymphoma and the development of biologic prognostic factors in Hodgkin lymphoma: tumor and microenvironment. Leuk Lymphoma. 2008 Sep; 49(9):1668-80. PMID: 18798102.
      Citations:    
    261. Lai R, Bartlett NL, Mackey JR, Jung SH, Johnson JL, Cook JR, Jones D, Cass CE, Young JD, Said J, Cheson B, Hsi ED. High expression of nucleoside transporter protein hENT1 in Reed-Sternberg cells is associated with treatment failure in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine and liposomal doxorubicin - a CALGB 59804 correlative study. Leuk Lymphoma. 2008 Jun; 49(6):1202-5. PMID: 18452103.
      Citations:    
    262. Gibson SE, Schade AE, Szpurka H, Bak B, Maciejewski JP, Hsi ED. Phospho-STAT5 expression pattern with the MPL W515L mutation is similar to that seen in chronic myeloproliferative disorders with JAK2 V617F. Hum Pathol. 2008 Jul; 39(7):1111-4. PMID: 18479730.
      Citations:    
    263. Hsi ED, Steinle R, Balasa B, Szmania S, Draksharapu A, Shum BP, Huseni M, Powers D, Nanisetti A, Zhang Y, Rice AG, van Abbema A, Wong M, Liu G, Zhan F, Dillon M, Chen S, Rhodes S, Fuh F, Tsurushita N, Kumar S, Vexler V, Shaughnessy JD, Barlogie B, van Rhee F, Hussein M, Afar DE, Williams MB. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res. 2008 May 01; 14(9):2775-84. PMID: 18451245.
      Citations:    
    264. Xie X, Sundram U, Natkunam Y, Kohler S, Hoppe RT, Kim YH, Cook JR, Hammel J, Swerdlow SH, Guitart J, Smith MD, Bosler D, Listinsky C, Lossos IS, Hsi ED. Expression of HGAL in primary cutaneous large B-cell lymphomas: evidence for germinal center derivation of primary cutaneous follicular lymphoma. Mod Pathol. 2008 Jun; 21(6):653-9. PMID: 18264083.
      Citations:    
    265. Natkunam Y, Farinha P, Hsi ED, Hans CP, Tibshirani R, Sehn LH, Connors JM, Gratzinger D, Rosado M, Zhao S, Pohlman B, Wongchaowart N, Bast M, Avigdor A, Schiby G, Nagler A, Byrne GE, Levy R, Gascoyne RD, Lossos IS. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab. J Clin Oncol. 2008 Jan 20; 26(3):447-54. PMID: 18086797.
      Citations:    
    266. Kelley TW, Pohlman B, Elson P, Hsi ED. The ratio of FOXP3+ regulatory T cells to granzyme B+ cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression. Am J Clin Pathol. 2007 Dec; 128(6):958-65. PMID: 18024321.
      Citations:    
    267. Gratzinger D, Zhao S, Tibshirani RJ, Hsi ED, Hans CP, Pohlman B, Bast M, Avigdor A, Schiby G, Nagler A, Byrne GE, Lossos IS, Natkunam Y. Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy. Lab Invest. 2008 Jan; 88(1):38-47. PMID: 17998899.
      Citations:    
    268. Bunting KD, Xie XY, Warshawsky I, Hsi ED. Cytoplasmic localization of phosphorylated STAT5 in human acute myeloid leukemia is inversely correlated with Flt3-ITD. Blood. 2007 Oct 01; 110(7):2775-6. PMID: 17881646.
      Citations:    
    269. Tsao L, Hsi ED. The clinicopathologic spectrum of posttransplantation lymphoproliferative disorders. Arch Pathol Lab Med. 2007 Aug; 131(8):1209-18. PMID: 17683183.
      Citations:    
    270. Zuluaga Toro T, Hsieh FH, Bodo J, Dong HY, Hsi ED. Detection of phospho-STAT5 in mast cells: a reliable phenotypic marker of systemic mast cell disease that reflects constitutive tyrosine kinase activation. Br J Haematol. 2007 Oct; 139(1):31-40. PMID: 17662084.
      Citations:    
    271. Zhao X, Qiu W, Kung J, Zhao X, Peng X, Yegappan M, Yen-Lieberman B, Hsi ED. Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: a gene expression profiling study with implications for potential combination therapies. Leuk Res. 2008 Feb; 32(2):275-85. PMID: 17659339.
      Citations:    
    272. Herling M, Patel KA, Hsi ED, Chang KC, Rassidakis GZ, Ford R, Jones D. TCL1 in B-cell tumors retains its normal b-cell pattern of regulation and is a marker of differentiation stage. Am J Surg Pathol. 2007 Jul; 31(7):1123-9. PMID: 17592280.
      Citations:    
    273. Gulley ML, Braziel RM, Halling KC, Hsi ED, Kant JA, Nikiforova MN, Nowak JA, Ogino S, Oliveira A, Polesky HF, Silverman L, Tubbs RR, Van Deerlin VM, Vance GH, Versalovic J. Clinical laboratory reports in molecular pathology. Arch Pathol Lab Med. 2007 Jun; 131(6):852-63. PMID: 17550311.
      Citations:    
    274. Smith SD, Bolwell BJ, Rybicki LA, Brown S, Dean R, Kalaycio M, Sobecks R, Andresen S, Hsi ED, Pohlman B, Sweetenham JW. Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen. Bone Marrow Transplant. 2007 Aug; 40(3):239-43. PMID: 17530000.
      Citations:    
    275. Korver W, Singh S, Liu S, Zhao X, Yonkovich S, Sweeney A, Anton K, Lomas WE, Greenwood R, Smith A, Tran DH, Shinkawa P, Jimenez M, Yeung P, Aguilar G, Palencia S, Vatta P, Mueller M, Zhan X, Newton EM, Liu Y, Zhao J, Emtage P, Levy MD, Hsi ED, Funk WD, Abo A. The lymphoid cell surface receptor NTB-A: a novel monoclonal antibody target for leukaemia and lymphoma therapeutics. Br J Haematol. 2007 May; 137(4):307-18. PMID: 17456053.
      Citations:    
    276. Warnke RA, Jones D, Hsi ED. Morphologic and immunophenotypic variants of nodal T-cell lymphomas and T-cell lymphoma mimics. Am J Clin Pathol. 2007 Apr; 127(4):511-27. PMID: 17369127.
      Citations:    
    277. Nikiforova MN, Hsi ED, Braziel RM, Gulley ML, Leonard DG, Nowak JA, Tubbs RR, Vance GH, Van Deerlin VM. Detection of clonal IGH gene rearrangements: summary of molecular oncology surveys of the College of American Pathologists. Arch Pathol Lab Med. 2007 Feb; 131(2):185-9. PMID: 17284101.
      Citations:    
    278. Aboudola S, Murugesan G, Szpurka H, Ramsingh G, Zhao X, Prescott N, Tubbs RR, Maciejewski JP, Hsi ED. Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation. Am J Surg Pathol. 2007 Feb; 31(2):233-9. PMID: 17255768.
      Citations:    
    279. Lu X, Chen J, Sasmono RT, Hsi ED, Sarosiek KA, Tiganis T, Lossos IS. T-cell protein tyrosine phosphatase, distinctively expressed in activated-B-cell-like diffuse large B-cell lymphomas, is the nuclear phosphatase of STAT6. Mol Cell Biol. 2007 Mar; 27(6):2166-79. PMID: 17210636.
      Citations:    
    280. Rodig SJ, Savage KJ, LaCasce AS, Weng AP, Harris NL, Shipp MA, Hsi ED, Gascoyne RD, Kutok JL. Expression of TRAF1 and nuclear c-Rel distinguishes primary mediastinal large cell lymphoma from other types of diffuse large B-cell lymphoma. Am J Surg Pathol. 2007 Jan; 31(1):106-12. PMID: 17197926.
      Citations:    
    281. Czuczman MS, Porcu P, Johnson J, Niedzwiecki D, Kelly M, Hsi ED, Cook JR, Canellos G, Cheson BD. Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901. Leuk Lymphoma. 2007 Jan; 48(1):97-103. PMID: 17325852.
      Citations:    
    282. Gibson SE, Dong HY, Advani AS, Hsi ED. Expression of the B cell-associated transcription factors PAX5, OCT-2, and BOB.1 in acute myeloid leukemia: associations with B-cell antigen expression and myelomonocytic maturation. Am J Clin Pathol. 2006 Dec; 126(6):916-24. PMID: 17074681.
      Citations:    
    283. Natkunam Y, Hsi ED, Aoun P, Zhao S, Elson P, Pohlman B, Naushad H, Bast M, Levy R, Lossos IS. Expression of the human germinal center-associated lymphoma (HGAL) protein identifies a subset of classic Hodgkin lymphoma of germinal center derivation and improved survival. Blood. 2007 Jan 01; 109(1):298-305. PMID: 16954503.
      Citations:    
    284. Vilchez RA, Jauregui MP, Hsi ED, Novoa-Takara L, Chang CC. Simian virus 40 in posttransplant lymphoproliferative disorders. Hum Pathol. 2006 Sep; 37(9):1130-6. PMID: 16938517.
      Citations:    
    285. Szpurka H, Tiu R, Murugesan G, Aboudola S, Hsi ED, Theil KS, Sekeres MA, Maciejewski JP. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. Blood. 2006 Oct 01; 108(7):2173-81. PMID: 16741247.
      Citations:    
    286. Dorfman DM, Bui MM, Tubbs RR, Hsi ED, Fitzgibbons PL, Linden MD, Rickert RR, Roche PC. The CD117 immunohistochemistry tissue microarray survey for quality assurance and interlaboratory comparison: a College of American Pathologists Cell Markers Committee Study. Arch Pathol Lab Med. 2006 Jun; 130(6):779-82. PMID: 16740027.
      Citations:    
    287. Hsi ED, Sup SJ, Alemany C, Tso E, Skacel M, Elson P, Alonso MA, Pohlman B. MAL is expressed in a subset of Hodgkin lymphoma and identifies a population of patients with poor prognosis. Am J Clin Pathol. 2006 May; 125(5):776-82. PMID: 16707382.
      Citations:    
    288. Wlodarski MW, Gondek LP, Nearman ZP, Plasilova M, Kalaycio M, Hsi ED, Maciejewski JP. Molecular strategies for detection and quantitation of clonal cytotoxic T-cell responses in aplastic anemia and myelodysplastic syndrome. Blood. 2006 Oct 15; 108(8):2632-41. PMID: 16614248.
      Citations:    
    289. Wongchaowart NT, Kim B, Hsi ED, Swerdlow SH, Tubbs RR, Cook JR. t(14;18)(q32;q21) involving IGH and MALT1 is uncommon in cutaneous MALT lymphomas and primary cutaneous diffuse large B-cell lymphomas. J Cutan Pathol. 2006 Apr; 33(4):286-92. PMID: 16630178.
      Citations:    
    290. Murugesan G, Aboudola S, Szpurka H, Verbic MA, Maciejewski JP, Tubbs RR, Hsi ED. Identification of the JAK2 V617F mutation in chronic myeloproliferative disorders using FRET probes and melting curve analysis. Am J Clin Pathol. 2006 Apr; 125(4):625-33. PMID: 16627272.
      Citations:    
    291. Cook JR, Hsi ED, Worley S, Tubbs RR, Hussein M. Immunohistochemical analysis identifies two cyclin D1+ subsets of plasma cell myeloma, each associated with favorable survival. Am J Clin Pathol. 2006 Apr; 125(4):615-24. PMID: 16627271.
      Citations:    
    292. Wongchaowart NT, Rinehart DG, Hsi ED. The correlation dimension identifies B-cell immunoglobulin light chain restriction in peripheral blood flow cytometry data. Am J Clin Pathol. 2006 Apr; 125(4):600-7. PMID: 16627269.
      Citations:    
    293. Winter JN, Weller EA, Horning SJ, Krajewska M, Variakojis D, Habermann TM, Fisher RI, Kurtin PJ, Macon WR, Chhanabhai M, Felgar RE, Hsi ED, Medeiros LJ, Weick JK, Reed JC, Gascoyne RD. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood. 2006 Jun 01; 107(11):4207-13. PMID: 16449523.
      Citations:    
    294. Kelley TW, Prayson RA, Barnett GH, Stevens GH, Cook JR, Hsi ED. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue arising in the lateral ventricle. Leuk Lymphoma. 2005 Oct; 46(10):1423-7. PMID: 16194887.
      Citations:    
    295. Patel RM, Goldblum JR, Hsi ED. Response to Pantanowitz et al. Regarding our paper on the utility of the detection of HHV-8 LNA-1 by immunohistochemistry in the diagnosis of Kaposi's sarcoma. Mod Pathol. 2005 Jul; 18(7):1011-2. PMID: 15968272.
      Citations:    
    296. Kelley TW, Huntsman D, McNagny KM, Roskelley CD, Hsi ED. Podocalyxin: a marker of blasts in acute leukemia. Am J Clin Pathol. 2005 Jul; 124(1):134-42. PMID: 15923169.
      Citations:    
    297. Marafioti T, Pozzobon M, Hansmann ML, Gaulard P, Barth TF, Copie-Bergman C, Roberton H, Ventura R, Martín-Subero JI, Gascoyne RD, Pileri SA, Siebert R, Hsi ED, Natkunam Y, Möller P, Mason DY. Expression pattern of intracellular leukocyte-associated proteins in primary mediastinal B cell lymphoma. Leukemia. 2005 May; 19(5):856-61. PMID: 15744341.
      Citations:    
    298. Sup SJ, Alemañy CA, Pohlman B, Elson P, Malhi S, Thakkar S, Steinle R, Hsi ED. Expression of bcl-2 in classical Hodgkin's lymphoma: an independent predictor of poor outcome. J Clin Oncol. 2005 Jun 01; 23(16):3773-9. PMID: 15809450.
      Citations:    
    299. Latif T, Hsi ED, Rybicki LA, Adelstein DJ. Is there a role for folate determinations in current clinical practice in the USA? Clin Lab Haematol. 2004 Dec; 26(6):379-83. PMID: 15595994.
      Citations:    
    300. Sup SJ, Domiati-Saad R, Kelley TW, Steinle R, Zhao X, Hsi ED. ZAP-70 expression in B-cell hematologic malignancy is not limited to CLL/SLL. Am J Clin Pathol. 2004 Oct; 122(4):582-7. PMID: 15487457.
      Citations:    
    301. Hsi ED. Pathology of primary cutaneous B-cell lymphomas: diagnosis and classification. Clin Lymphoma. 2004 Sep; 5(2):89-97. PMID: 15453923.
      Citations:    
    302. Hsi ED, Mirza I, Lozanski G, Hill J, Pohlman B, Karafa MT, Coupland R. A clinicopathologic evaluation of follicular lymphoma grade 3A versus grade 3B reveals no survival differences. Arch Pathol Lab Med. 2004 Aug; 128(8):863-8. PMID: 15270618.
      Citations:    
    303. Kelley TW, Alkan S, Srkalovic G, Hsi ED. Treatment of human chronic lymphocytic leukemia cells with the proteasome inhibitor bortezomib promotes apoptosis. Leuk Res. 2004 Aug; 28(8):845-50. PMID: 15203282.
      Citations:    
    304. Wang-Gillam A, Lee RS, Hsi ED, Brotman DJ. Acute splenic sequestration crisis resembling sepsis in an adult with hemoglobin SC disease. South Med J. 2004 Apr; 97(4):413-5. PMID: 15108841.
      Citations:    
    305. Patel RM, Goldblum JR, Hsi ED. Immunohistochemical detection of human herpes virus-8 latent nuclear antigen-1 is useful in the diagnosis of Kaposi sarcoma. Mod Pathol. 2004 Apr; 17(4):456-60. PMID: 14990970.
      Citations:    
    306. Hsi ED, Tubbs RR. Guidelines for HER2 testing in the UK. J Clin Pathol. 2004 Mar; 57(3):241-2. PMID: 14990591.
      Citations:    
    307. Tubbs RR, Hsi ED, Hicks D, Goldblum J. Molecular pathology testing of tissues fixed in prefer solution. Am J Surg Pathol. 2004 Mar; 28(3):417-9. PMID: 15104311.
      Citations:    
    308. Hsi ED, Frater JL. Advances in the diagnosis and classification of chronic lymphoproliferative disorders. Cancer Treat Res. 2004; 121:145-65. PMID: 15217209.
      Citations:    
    309. Beck RC, Stahl S, O'Keefe CL, Maciejewski JP, Theil KS, Hsi ED. Detection of mature T-cell leukemias by flow cytometry using anti-T-cell receptor V beta antibodies. Am J Clin Pathol. 2003 Nov; 120(5):785-94. PMID: 14608907.
      Citations:    
    310. Ramalingam P, Chu WS, Tubbs R, Rybicki L, Pettay J, Hsi ED. Latent membrane protein 1, tumor necrosis factor receptor-associated factor (TRAF) 1, TRAF-2, TRAF-3, and nuclear factor kappa B expression in posttransplantation lymphoproliferative disorders. Arch Pathol Lab Med. 2003 Oct; 127(10):1335-9. PMID: 14521460.
      Citations:    
    311. Latif T, Pohlman B, Kalaycio M, Sobecks R, Hsi ED, Andresen S, Bolwell BJ. Syngeneic graft-versus-host disease: a report of two cases and literature review. Bone Marrow Transplant. 2003 Sep; 32(5):535-9. PMID: 12942102.
      Citations:    
    312. Hsi ED, Mirza I. Update in the pathologic features of mature B-cell and T/NK-cell leukemias. Semin Diagn Pathol. 2003 Aug; 20(3):180-95. PMID: 14552430.
      Citations:    
    313. Hsi ED, Kopecky KJ, Appelbaum FR, Boldt D, Frey T, Loftus M, Hussein MA. Prognostic significance of CD38 and CD20 expression as assessed by quantitative flow cytometry in chronic lymphocytic leukaemia. Br J Haematol. 2003 Mar; 120(6):1017-25. PMID: 12648072.
      Citations:    
    314. Beck RC, Tubbs RR, Hussein M, Pettay J, Hsi ED. Automated colorimetric in situ hybridization (CISH) detection of immunoglobulin (Ig) light chain mRNA expression in plasma cell (PC) dyscrasias and non-Hodgkin lymphoma. Diagn Mol Pathol. 2003 Mar; 12(1):14-20. PMID: 12605031.
      Citations:    
    315. Perez-Zincer F, Juturi JV, Hsi ED, Hoeltge GA, Rybicki LA, Kalaycio ME. A pulmonary syndrome in patients with acute myelomonocytic leukemia and inversion of chromosome 16. Leuk Lymphoma. 2003 Jan; 44(1):103-9. PMID: 12691148.
      Citations:    
    316. Hsi ED, Tubbs RR, Lovell MA, Braziel RM, Gulley ML. Detection of bcl-2/J(H) translocation by polymerase chain reaction: a summary of the experience of the Molecular Oncology Survey of the College of American Pathologist. Arch Pathol Lab Med. 2002 Aug; 126(8):902-8. PMID: 12171487.
      Citations:    
    317. Hsi ED, Mirza I, Gascoyne RD. Absence of t(14,18) chromosomal translocation in primary cutaneous B-cell lymphoma. Br J Dermatol. 2002 Jun; 146(6):1110-1; author reply 1111-2. PMID: 12072097.
      Citations:    
    318. Ramalingam P, Rybicki L, Smith MD, Abrahams NA, Tubbs RR, Pettay J, Farver CF, Hsi ED. Posttransplant lymphoproliferative disorders in lung transplant patients: the Cleveland Clinic experience. Mod Pathol. 2002 Jun; 15(6):647-56. PMID: 12065779.
      Citations:    
    319. Skacel M, Paris PL, Pettay JD, Tsiftsakis EK, Tubbs RR, Casey G, Hsi ED. Diffuse large B-cell lymphoma of the stomach: assessment of microsatellite instability, allelic imbalance, and trisomy of chromosomes 3, 12, and 18. Diagn Mol Pathol. 2002 Jun; 11(2):75-82. PMID: 12045710.
      Citations:    
    320. Hembury TA, Lee B, Gascoyne RD, Macpherson N, Yang B, House N, Medeiros LJ, Hsi ED. Primary cutaneous diffuse large B-cell lymphoma: a clinicopathologic study of 15 cases. Am J Clin Pathol. 2002 Apr; 117(4):574-80. PMID: 11939732.
      Citations:    
    321. Mirza I, Macpherson N, Paproski S, Gascoyne RD, Yang B, Finn WG, Hsi ED. Primary cutaneous follicular lymphoma: an assessment of clinical, histopathologic, immunophenotypic, and molecular features. J Clin Oncol. 2002 Feb 01; 20(3):647-55. PMID: 11821444.
      Citations:    
    322. Trupiano JK, Bringelsen K, Hsi ED. Primary cutaneous lymphoblastic lymphoma presenting in an 8-week old infant. J Cutan Pathol. 2002 Feb; 29(2):107-12. PMID: 12150131.
      Citations:    
    323. Connors JM, Hsi ED, Foss FM. Lymphoma of the skin. Hematology Am Soc Hematol Educ Program. 2002; 263-82. PMID: 12446427.
      Citations:    
    324. Frater JL, Hsi ED. Properties of the mantle cell and mantle cell lymphoma. Curr Opin Hematol. 2002 Jan; 9(1):56-62. PMID: 11753079.
      Citations:    
    325. Frater JL, Tsiftsakis EK, Hsi ED, Pettay J, Tubbs RR. Use of novel t(11;14) and t(14;18) dual-fusion fluorescence in situ hybridization probes in the differential diagnosis of lymphomas of small lymphocytes. Diagn Mol Pathol. 2001 Dec; 10(4):214-22. PMID: 11763311.
      Citations:    
    326. Frater JL, McCarron KF, Hammel JP, Shapiro JL, Miller ML, Tubbs RR, Pettay J, Hsi ED. Typical and atypical chronic lymphocytic leukemia differ clinically and immunophenotypically. Am J Clin Pathol. 2001 Nov; 116(5):655-64. PMID: 11710681.
      Citations:    
    327. Yegappan S, Coupland R, Arber DA, Wang N, Miocinovic R, Tubbs RR, Hsi ED. Angiotropic lymphoma: an immunophenotypically and clinically heterogeneous lymphoma. Mod Pathol. 2001 Nov; 14(11):1147-56. PMID: 11706077.
      Citations:    
    328. Chen Q, Gong B, Mahmoud-Ahmed AS, Zhou A, Hsi ED, Hussein M, Almasan A. Apo2L/TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma. Blood. 2001 Oct 01; 98(7):2183-92. PMID: 11568006.
      Citations:    
    329. Hsi ED. Towards a molecular classification of hematolymphoid neoplasms: where are we now? Where are we going? J Histochem Cytochem. 2001 Oct; 49(10):1323-4. PMID: 11561018.
      Citations:    
    330. Ormsby A, Bergfeld WF, Tubbs RR, Hsi ED. Evaluation of a new paraffin-reactive CD7 T-cell deletion marker and a polymerase chain reaction-based T-cell receptor gene rearrangement assay: implications for diagnosis of mycosis fungoides in community clinical practice. J Am Acad Dermatol. 2001 Sep; 45(3):405-13. PMID: 11511839.
      Citations:    
    331. Hsi ED, Yegappan S. Lymphoma immunophenotyping: a new era in paraffin-section immunohistochemistry. Adv Anat Pathol. 2001 Jul; 8(4):218-39. PMID: 11444510.
      Citations:    
    332. Wrone-Smith T, Izban KF, Ergin M, Cosar EF, Hsi ED, Alkan S. Transfection of caspase-3 in the caspase-3-deficient Hodgkin's disease cell line, KMH2, results in enhanced sensitivity to CD95-, TRAIL-, and ARA-C-induced apoptosis. Exp Hematol. 2001 May; 29(5):572-81. PMID: 11376869.
      Citations:    
    333. Shehab TM, Hsi ED, Poterucha JJ, Gunaratnam NT, Fontana RJ. Helicobacter pylori-associated gastric MALT lymphoma in liver transplant recipients. Transplantation. 2001 Apr 27; 71(8):1172-5. PMID: 11374421.
      Citations:    
    334. Hsi ED. The search for meaningful prognostic markers in diffuse large B-cell lymphoma. Am J Clin Pathol. 2001 Apr; 115(4):481-3. PMID: 11293894.
      Citations:    
    335. Yegappan S, Schnitzer B, Hsi ED. Follicular lymphoma with marginal zone differentiation: microdissection demonstrates the t(14;18) in both the follicular and marginal zone components. Mod Pathol. 2001 Mar; 14(3):191-6. PMID: 11266525.
      Citations:    
    336. Hsi ED. A practical approach for evaluating new antibodies in the clinical immunohistochemistry laboratory. Arch Pathol Lab Med. 2001 Feb; 125(2):289-94. PMID: 11175655.
      Citations:    
    337. Hsi ED. Paroxysmal nocturnal hemoglobinuria testing by flow cytometry. Evaluation of the REDQUANT and CELLQUANT kits. Am J Clin Pathol. 2000 Nov; 114(5):798-806. PMID: 11068556.
      Citations:    
    338. Izban KF, Alkan S, Singleton TP, Hsi ED. Multiparameter immunohistochemical analysis of the cell cycle proteins cyclin D1, Ki-67, p21WAF1, p27KIP1, and p53 in mantle cell lymphoma. Arch Pathol Lab Med. 2000 Oct; 124(10):1457-62. PMID: 11035575.
      Citations:    
    339. Skacel M, Ross CW, Hsi ED. A reassessment of primary thyroid lymphoma: high-grade MALT-type lymphoma as a distinct subtype of diffuse large B-cell lymphoma. Histopathology. 2000 Jul; 37(1):10-8. PMID: 10931213.
      Citations:    
    340. McCarron KF, Hammel JP, Hsi ED. Usefulness of CD79b expression in the diagnosis of B-cell chronic lymphoproliferative disorders. Am J Clin Pathol. 2000 Jun; 113(6):805-13. PMID: 10874881.
      Citations:    
    341. Hsi ED, Hoeltge G, Tubbs RR. Biclonal chronic lymphocytic leukemia. Am J Clin Pathol. 2000 Jun; 113(6):798-804. PMID: 10874880.
      Citations:    
    342. Yang F, Tran TA, Carlson JA, Hsi ED, Ross CW, Arber DA. Paraffin section immunophenotype of cutaneous and extracutaneous mast cell disease: comparison to other hematopoietic neoplasms. Am J Surg Pathol. 2000 May; 24(5):703-9. PMID: 10800989.
      Citations:    
    343. Yang B, Tubbs RR, Finn W, Carlson A, Pettay J, Hsi ED. Clinicopathologic reassessment of primary cutaneous B-cell lymphomas with immunophenotypic and molecular genetic characterization. Am J Surg Pathol. 2000 May; 24(5):694-702. PMID: 10800988.
      Citations:    
    344. Schumann KW, Oriba HA, Bergfeld WF, Hsi ED, Hollandsworth K. Cutaneous presentation of posttransplant lymphoproliferative disorder. J Am Acad Dermatol. 2000 May; 42(5 Pt 2):923-6. PMID: 10767706.
      Citations:    
    345. Sigel JE, Hsi ED. Immunohistochemical analysis of CD30-positive lymphoproliferative disorders for expression of CD95 and CD95L. Mod Pathol. 2000 Apr; 13(4):446-51. PMID: 10786813.
      Citations:    
    346. Hsi ED, Singleton TP, Swinnen L, Dunphy CH, Alkan S. Mucosa-associated lymphoid tissue-type lymphomas occurring in post-transplantation patients. Am J Surg Pathol. 2000 Jan; 24(1):100-6. PMID: 10632493.
      Citations:    
    347. Raible MD, Hsi ED, Alkan S. Bcl-6 protein expression by follicle center lymphomas. A marker for differentiating follicle center lymphomas from other low-grade lymphoproliferative disorders. Am J Clin Pathol. 1999 Jul; 112(1):101-7. PMID: 10396291.
      Citations:    
    348. Kolenko V, Uzzo RG, Bukowski R, Bander NH, Novick AC, Hsi ED, Finke JH. Dead or dying: necrosis versus apoptosis in caspase-deficient human renal cell carcinoma. Cancer Res. 1999 Jun 15; 59(12):2838-42. PMID: 10383143.
      Citations:    
    349. Uzzo RG, Rayman P, Kolenko V, Clark PE, Bloom T, Ward AM, Molto L, Tannenbaum C, Worford LJ, Bukowski R, Tubbs R, Hsi ED, Bander NH, Novick AC, Finke JH. Mechanisms of apoptosis in T cells from patients with renal cell carcinoma. Clin Cancer Res. 1999 May; 5(5):1219-29. PMID: 10353760.
      Citations:    
    350. Izban KF, Wrone-Smith T, Hsi ED, Schnitzer B, Quevedo ME, Alkan S. Characterization of the interleukin-1beta-converting enzyme/ced-3-family protease, caspase-3/CPP32, in Hodgkin's disease: lack of caspase-3 expression in nodular lymphocyte predominance Hodgkin's disease. Am J Pathol. 1999 May; 154(5):1439-47. PMID: 10329597.
      Citations:    
    351. Izban KF, Candel AG, Hsi ED, Selvaggi SM. Metastatic melanoma of the vulva identified by peritoneal fluid cytology. Diagn Cytopathol. 1999 Mar; 20(3):152-5. PMID: 10086239.
      Citations:    
    352. de Leon ED, Alkan S, Huang JC, Hsi ED. Usefulness of an immunohistochemical panel in paraffin-embedded tissues for the differentiation of B-cell non-Hodgkin's lymphomas of small lymphocytes. Mod Pathol. 1998 Nov; 11(11):1046-51. PMID: 9831200.
      Citations:    
    353. Izban KF, Nawrocki JF, Alkan S, Hsi ED. Monoclonal IgH gene rearrangement in microdissected nodules from nodular sclerosis Hodgkin disease. Am J Clin Pathol. 1998 Nov; 110(5):599-606. PMID: 9802344.
      Citations:    
    354. Tworek JA, Singleton TP, Schnitzer B, Hsi ED, Ross CW. Flow cytometric and immunohistochemical analysis of small lymphocytic lymphoma, mantle cell lymphoma, and plasmacytoid small lymphocytic lymphoma. Am J Clin Pathol. 1998 Nov; 110(5):582-9. PMID: 9802342.
      Citations:    
    355. Izban KF, Hsi ED, Alkan S. Immunohistochemical analysis of mycosis fungoides on paraffin-embedded tissue sections. Mod Pathol. 1998 Oct; 11(10):978-82. PMID: 9796726.
      Citations:    
    356. Kroft SH, Hsi ED, Ross CW, Schnitzer B, Singleton TP. Evaluation of CD23 expression in paraffin-embedded gastric lymphomas of mucosa-associated lymphoid tissue. Mod Pathol. 1998 Oct; 11(10):967-70. PMID: 9796724.
      Citations:    
    357. Hsi ED, Singleton TP, Svoboda SM, Schnitzer B, Ross CW. Characterization of the lymphoid infiltrate in Hashimoto thyroiditis by immunohistochemistry and polymerase chain reaction for immunoglobulin heavy chain gene rearrangement. Am J Clin Pathol. 1998 Sep; 110(3):327-33. PMID: 9728607.
      Citations:    
    358. Hsi ED, Picken MM, Alkan S. Post-transplantation lymphoproliferative disorder of the NK-cell type: a case report and review of the literature. Mod Pathol. 1998 May; 11(5):479-84. PMID: 9619602.
      Citations:    
    359. Hsi ED, Foreman KE, Duggan J, Alkan S, Kauffman CA, Aronow HD, Nickoloff BJ. Molecular and pathologic characterization of an AIDS-related body cavity-based lymphoma, including ultrastructural demonstration of human herpesvirus-8: a case report. Am J Surg Pathol. 1998 Apr; 22(4):493-9. PMID: 9537479.
      Citations:    
    360. Hsi ED, Eisbruch A, Greenson JK, Singleton TP, Ross CW, Schnitzer B. Classification of primary gastric lymphomas according to histologic features. Am J Surg Pathol. 1998 Jan; 22(1):17-27. PMID: 9422312.
      Citations:    
    361. Kroft SH, Singleton TP, Dahiya M, Ross CW, Schnitzer B, Hsi ED. Ruptured spleens with expanded marginal zones do not reveal occult B-cell clones. Mod Pathol. 1997 Dec; 10(12):1214-20. PMID: 9436966.
      Citations:    
    362. Foreman KE, Bacon PE, Hsi ED, Nickoloff BJ. In situ polymerase chain reaction-based localization studies support role of human herpesvirus-8 as the cause of two AIDS-related neoplasms: Kaposi's sarcoma and body cavity lymphoma. J Clin Invest. 1997 Jun 15; 99(12):2971-8. PMID: 9185521.
      Citations:    
    363. Hsi ED, Svoboda-Newman SM, Stern RA, Nickoloff BJ, Frank TS. Detection of human papillomavirus DNA in keratoacanthomas by polymerase chain reaction. Am J Dermatopathol. 1997 Feb; 19(1):10-5. PMID: 9056648.
      Citations:    
    364. Hsi ED, Siddiqui J, Schnitzer B, Alkan S, Ross CW. Analysis of immunoglobulin heavy chain gene rearrangement in myoepithelial sialadenitis by polymerase chain reaction. Am J Clin Pathol. 1996 Oct; 106(4):498-503. PMID: 8853039.
      Citations:    
    365. Frank TS, Svoboda-Newman SM, Hsi ED. Comparison of methods for extracting DNA from formalin-fixed paraffin sections for nonisotopic PCR. Diagn Mol Pathol. 1996 Sep; 5(3):220-4. PMID: 8866237.
      Citations:    
    366. Hsi ED, Zukerberg LR, Yang WI, Arnold A. Cyclin D1/PRAD1 expression in parathyroid adenomas: an immunohistochemical study. J Clin Endocrinol Metab. 1996 May; 81(5):1736-9. PMID: 8626826.
      Citations:    
    367. Hsi ED, Greenson JK, Singleton TP, Siddiqui J, Schnitzer B, Ross CW. Detection of immunoglobulin heavy chain gene rearrangement by polymerase chain reaction in chronic active gastritis associated with Helicobacter pylori. Hum Pathol. 1996 Mar; 27(3):290-6. PMID: 8600045.
      Citations:    
    368. Hsi ED, Nickoloff BJ. Dermatofibroma and dermatofibrosarcoma protuberans: an immunohistochemical study reveals distinctive antigenic profiles. J Dermatol Sci. 1996 Jan; 11(1):1-9. PMID: 8867761.
      Citations:    
    369. Hsi ED, Zukerberg LR, Schnitzer B, Harris NL. Development of extrasalivary gland lymphoma in myoepithelial sialadenitis. Mod Pathol. 1995 Oct; 8(8):817-24. PMID: 8552569.
      Citations:    
    370. Hsi ED, Remick DG. Monocytes are the major producers of interleukin-1 beta in an ex vivo model of local cytokine production. J Interferon Cytokine Res. 1995 Jan; 15(1):89-94. PMID: 7648438.
      Citations:    
    371. Hsi ED, Remick DG. Rapid determination of cell-associated tumor necrosis factor production by flow cytometry. Lab Invest. 1993 Jun; 68(6):740-5. PMID: 8515659.
      Citations:    
    372. Nakayama T, Singer A, Hsi ED, Samelson LE. Intrathymic signalling in immature CD4+CD8+ thymocytes results in tyrosine phosphorylation of the T-cell receptor zeta chain. Nature. 1989 Oct 19; 341(6243):651-4. PMID: 2477711.
      Citations:    
    373. Hsi ED, Siegel JN, Minami Y, Luong ET, Klausner RD, Samelson LE. T cell activation induces rapid tyrosine phosphorylation of a limited number of cellular substrates. J Biol Chem. 1989 Jun 25; 264(18):10836-42. PMID: 2786526.
      Citations:    
    Hsi's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (881)
    Explore
    _
    Co-Authors (5)
    Explore
    _
    Same Department Expand Description
    Explore
    _